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Abstract 
Dementia is a very delicate disease that not only affects the patients, but also 
everyone around them. Nearly 36 million people live with dementia, and future does not 
appear to shine brighter since for the year 2050 the prognosis is that this number will 
triple. Alzheimer’s disease (AD) is the most prevalent form of dementia (75% of all cases), 
independently of age, and is mainly characterized by the presence of senile plaques (SPs) 
and neurofibrillary tangles (NFTs), accompanied by progressive dementia. Transthyretin 
(TTR) has been shown, through in vitro and in vivo studies, to exhibit a neuroprotective 
role in AD, however, its underlying mechanisms are still vastly unknown. With this project, 
we proposed a dual investigation: first, the study of two distinct proteins – sortilin (Sort1) 
and synaptophysin (Syp) – that were suggested to be altered in AD, and thus, assess its 
potential as a biomarker; and second, evaluate TTR’s role in disease and its effect on 
these prospective biomarkers. All the experiments were performed in a transgenic AD 
mouse model bearing different TTR genetic backgrounds (two copies of the mouse TTR 
gene – AD/TTR+/+, and one copy of the mouse TTR gene – AD/TTR+/-), which was 
previously described in our laboratory. All the results were obtained through Western Blot 
analysis, using 3- and 7-months old AD/TTR mice. From this analysis we show that Sort1 
is decreased at both ages in AD/TTR+/- mice, in relation to AD/TTR+/+, and suggest that 
due to its behavior, this protein could be used for early AD detection, even when β-
amyloid (Aβ) deposits are absent, and follow-up of therapies. Still regarding Sort1, female 
gender appears to be more affected since it showed a more accentuated decrease, 
compared to males. This is especially observed in older mice, thus showing the impact of 
aging in AD. As for Syp, we observed an increase in its expression for 3 months-old 
AD/TTR+/- mice, compared to AD/TTR+/+, contrary to 7 months-old mice that showed no 
significant differences. Thus, we suggested that this alteration was due to an overlapping 
effect of aging over TTR reduction. Nonetheless, we also propose that Syp should be 
considered for further studies as an early AD detection biomarker. Alterations observed 
for both Sort1 and Syp were not restored in AD/TTR+/- mice treated with iododiflunisal 
(IDIF), known to stabilize TTR and shown to improve AD features, namely Aβ levels and 
deposition in the brain, and cognition in this mouse model. This indicates that Sort1 and 
Syp are dependent on TTR quantity and that its stabilization was not sufficient to reverse 
the effects of the TTR genetically reduced levels. 
Keywords: Alzheimer’s disease; biomarker; transthyretin; sortilin; synaptophysin; 
transgenic mouse model.   
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Resumo 
Demência é uma condição bastante delicada que afeta não só o paciente, como 
também todos aqueles que o rodeiam. Aproximadamente 36 milhões de pessoas vivem 
com esta doença e o futuro não se apresenta brilhante, dado que o prognóstico para 
2050 é de que este número irá triplicar. A Doença de Alzheimer (DA) é a forma mais 
prevalente de demência (75% de todos os casos), independentemente da idade, e é 
principalmente caracterizada pela presença de placas senis e emaranhados 
neurofibrilares, acompanhados de uma demência progressiva. À proteína transtirretina foi 
associado um papel neuroprotetor na DA, através de estudos in vitro e in vivo, porém, os 
mecanismos moleculares responsáveis por este papel são ainda imensamente 
desconhecidos. Através deste projeto, propusemos uma investigação bi-objectiva: em 
primeiro lugar, estudar duas proteínas distintas – sortilina (Sort1) e sinaptofisina (Syp) – 
que se verificaram estar alteradas na DA, e assim, averiguar o seu potencial como 
possível biomarcador; e em segundo lugar, avaliar o papel da TTR nesta doença e o seu 
efeito nas proteínas atrás referidas. Todas as experiências foram realizadas usando um 
modelo de murganho transgénico para DA, com diferentes genótipos de TTR (duas 
cópias do gene TTR de murganho – AD/TTR+/+, e uma cópia do gene TTR de murganho 
– AD/TTR+/-), previamente descrito no nosso laboratório. Todos os resultados foram 
obtidos através de análise por Western Blot, usando murganhos AD/TTR de 3 e 7 meses 
de idade. Desta análise surgiu que a Sort1 se apresenta diminuída em ambas as idades, 
nos murganhos AD/TTR+/-, em comparação com os AD/TTR+/+, sendo possível sugerir 
que, dado o seu comportamento, esta proteína poderá ser usada na deteção precoce de 
DA, mesmo quando é ausente a deposição de β-amiloide. Ainda sobre a Sort1, observou-
se uma diminuição mais acentuada dos seus níveis no sexo feminino, em relação ao 
masculino, sugerindo então que o primeiro se encontra mais afetado. Esta diminuição 
encontra-se especialmente demarcada nos murganhos de 7 meses, o que demonstra o 
impacto do envelhecimento na DA. Em relação à Syp, observámos um aumento da sua 
expressão em murganhos AD/TTR+/- de 3 meses de idade, em oposição ao observado 
para murganhos de 7 meses, onde as diferenças não foram consideradas significativas. 
Sendo assim, sugerimos que esta alteração do comportamento de expressão da Syp é 
devida a um efeito do envelhecimento, que aparenta anular qualquer efeito proveniente 
da redução genética da TTR. No entanto, propomos que futuros estudos sobre a Syp 
(enquanto biomarcador) sejam realizados, uma vez que esta parece apropriada para a 
deteção de estádios precoces na DA. As alterações de expressão na Sort1 e Syp não 
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foram restauradas em murganhos AD/TTR+/- tratados com iododiflunisal (IDIF), um 
composto que promove a estabilização da TTR e o melhoramento das características da 
DA neste modelo animal (nomeadamente, níveis de Aβ e deposição no cérebro, e 
cognição). Tal indica que a Sort1 e a Syp são dependentes da quantidade de TTR e que 
mesmo a sua estabilização não é suficiente para reverter os efeitos da redução genética 
da TTR. 
Palavras-chave: Doença de Alzheimer; biomarcador; transtirretina; sortilina; 
sinaptofisina; modelo de murganho transgénico. 
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Introduction 
 
“If any one faculty of our nature may be called more wonderful than the rest, I do think 
it is memory. There seems something more speakingly incomprehensible in the powers, 
the failures, the inequalities of memory, than in any other of our intelligences. The memory 
is sometimes so retentive, so serviceable, so obedient; at others, so bewildered and so 
weak; and at others again, so tyrannic, so beyond control! We are, to be sure, a miracle 
every way; but our powers of recollecting and of forgetting do seem peculiarly past finding 
out.” 
by Jane Austen, Mansfield Park 
 
All around the world, dementia is one of the major concerns for society, independently 
of the socio-economic status. Nearly 36 million people live with dementia, and the 
prognosis is that by 2050 this number will triple (115 million)[2]. Within the cases of 
dementia, Alzheimer’s disease (AD) occupies a special place, counting up to 75% of all 
cases[3, 4]. Different kinds of dementia, in addition to AD, have been characterized and 
within this list we can find vascular dementia, dementia with Lewy bodies, mixed 
dementia, Parkinson’s disease, and Creutzfeldt-Jakob disease[5], among others. One of 
the major problems of AD, and other dementias, is the lack of early diagnosis techniques, 
whereas, in more late-stages AD is identified quite accurately by most clinicians[6]. In 
effect, definite AD (considered a dual clinicopathological entity[7]) is only diagnosed after 
postmortem evidence of extracellular amyloid (or senile) plaques and intracellular 
neurofibrillary tangles[8], presented with progressive dementia. They are considered 
pathognomonic signs (characteristic for a particular disease – from the Greek: páthos 
meaning “disease”, and gnõmon, meaning “judge”) for AD and so, after autopsy, their 
presence is used to verify the diagnosis. 
Therefore, the uncertainty of the underlying diagnosis is a tremendous hurdle in the 
development of new therapies[6]. Despite of all the efforts, AD is still an incurable 
neurodegenerative disease. 
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Introducing Alzheimer 
Alois Alzheimer (Figure 1) was born on 14 June 1864, in Marktbreit, Bavaria, and is 
considered one of the founding fathers of neuropathology. He was attributed the credits 
for discovering and describing a so-called “presenile dementia”, which would be later 
named after him, in 1910, by his colleague Emil Kraepelin[9, 10]. With the simplest 
sentence: “The clinical interpretation of this Alzheimer’s disease is still unclear.” of the 
famous Textbook of Psychiatry (Psychiatrie: Ein Lehrbuch fur Studierend and Aerzt)[11] 
Kraepelin immortalized Alois Alzheimer. Alzheimer made fundamental contributions to 
understand other diseases such as vascular dementia, Huntington’s disease, syphilis, 
brain tumors and epilepsy. He died from rheumatic endocarditis[9], curiously at the age of 
51. 
 
Alzheimer’s disease was first described in the 1907’s paper entitled "Uber eine 
eigenartige Erkankung der Hirnrinde", by Alois Alzheimer. In it, the author described the 
behavior of a 51-year-old female patient (Figure 1) of the insane asylum of Frankfurt am 
Main. She (Auguste Deter) presented several symptoms that caught Alzheimer’s 
attention, apart from the central nervous system anatomical characteristics. Among them, 
time and space disorientation, rapid loss of memory and mood swings were the most 
prominent symptoms[12]. In relation to pathological features, the observation of “thick 
bundles”[12] of fibrils (later known as senile/amyloid plaques and neurofibrillary 
tangles[13]) made AD a unique condition, distinguishing it from the other neurological 
conditions known[14]. 
After the initial work by Alois Alzheimer, scientists have been successively and 
continuously motivated to acquire the necessary knowledge to comprehend and unveil the 
  
Figure 1. Alois Alzheimer (left) and its first patient, Auguste Deter (right). 
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mysteries that surround this intriguing disease.  And so, due to the outstanding work made 
by Alois Alzheimer’s “followers”, advances have been made, leading them closer to a 
possible cure. Amyloid-beta (Aβ) immunotherapy[15, 16], gene therapy[17], and deep 
brain stimulation[18, 19] are good examples of scientists’ determination (in the most 
distinct fields) to achieve the ultimate goal, the cure for Alzheimer’s disease. 
 
By the eyes of Alzheimer 
Alzheimer’s disease is a progressive neurodegenerative disease and the most 
common case of dementia[20], covering a heterogeneous group of disorders[10] with 
increasing prevalence after the age 65[14]. Although AD is seen as an elderly disease due 
to its higher prevalence in the older population, it is also the most frequent form of 
dementia under the age of 65[21, 22]. More recently, in 2011, the National Institute of 
Aging and the Alzheimer’s Association recommended new diagnostic criteria and 
guidelines, proposing three different stages for AD: (1) preclinical Alzheimer’s disease; (2) 
mild cognitive impairment due to Alzheimer’s disease; and (3) dementia due to 
Alzheimer’s disease[5]. Genetically, AD is usually divided in two forms: autosomal 
dominant familial AD (FAD; Mendelian inheritance predominantly of early-onset – 
EOAD[23]) and sporadic AD (also called late-onset AD – LOAD), counting the latter as 
95% of all AD cases[7]. 
In FAD, autosomal mutations capable of triggering the disease were identified, mainly, 
in three distinct genes: amyloid precursor protein (APP)[24, 25] gene, presenilin 1 
(PSEN1) and presenilin 2 (PSEN2) genes[26], in chromosomes 21q, 14q and 1q, 
respectively. Together, these mutations (more than 200 mutations known) are responsible 
for less than 1% of all cases of AD (http://www.molgen.vib-ua.be/ADMutations/). Contrary 
to FAD, sporadic AD does not exhibit autosomal-dominant inheritance but up to 60%-80% 
of this form of AD is genetically determined[23]. Thus, genetic risk factors are extensively 
studied, being the apolipoprotein E (ApoE) gene, in chromosome 19, an excellent 
example.  
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1. Increasing the risk 
ApoE exists as three isoforms ε2, ε3 and ε4, with ε3 having the highest prevalence, 
and it plays an important role in AD, since the risk of developing disease is increased in 
carriers of the ApoE-ε4 allele. In 1993 the group of E.H. Corder stated that individuals with 
one and two copies of the ε4 allele have, respectively, a 45% and 50–90% probability of 
developing AD[27], and that a double dose of ApoE-ε4 allele was nearly enough to cause 
AD by age 80[28]. Despite the broad molecular evidence about ApoE’s role in AD, its 
genetic variation is also present in other kinds of neurological disorders including 
Parkinson’s disease and multiple sclerosis[23]. In 2009, three novel AD genes were 
identified, presenting high degree of association: CLU (clusterin or apolipoprotein J – 
ApoJ), CR1 (complement component (3b/4b) receptor 1), and PICALM 
(phosphatidylinositol binding clathrin assembly protein)[23]. 
As Stephen King wrote in The Gunslinger: “Time's the thief of memory”. Thus, in 
addition to the genetic risk, a well established (and intuitive) risk factor is aging, since in 
every species age brings a slowing of brain function[29]. It is considered the most 
important factor specially due to the increasing of life expectancy worldwide, in addition to 
the increasing of population, which in turn can be attributed to the postwar “baby boom”. 
Other risk factors, such as: diabetes mellitus[30], obesity, hypertension, metabolic 
syndrome, hypercholesterolemia[31], Down’s syndrome[32], traumatic brain injury[33], 
gender, education[34] (female gender and low educational level with increased risk), 
social engagement, and diet, have been increasing evidence. Contrasting with the 
previous risk factors, wine consumption, coffee consumption, the use of non-steroidal anti-
inflammatory drugs (NSAIDs), and a good balance of metal ions [35] are associated with 
reduced risks, thus showing some protective effects[34]. 
2. Symptoms and afflictions 
In terms of symptoms, it is possible to divide and group them in three simple 
categories: (1) cognitive deficits that affect memory (amnesia and agnosia), speech 
(aphasia), and motor function (apraxia)[29]; (2) various psychiatric symptoms and 
behavioral disturbances such as depression, social withdrawal[8], personality changes, 
delusions, hallucinations, and misidentification[7, 20]; (3) difficulties with the daily living 
activities, such as driving, using the telephone, dealing with money and, later in the 
disease, all the basic needs (feeding, dressing, toileting)[20]. As one would expect, with 
disease progression the intensity of the symptoms increases and also, patients start to 
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become increasingly more dependent on others to do their every day chores. Hence, this 
disease does not just affect the life of patients but also the life of their caregivers.  
3. How does it work? 
All visible symptoms arise from the alteration and loss of structural complexity of our 
brain cells [29], which can begin as many as 20 years before symptoms appear[5]. Thus, 
all the above symptoms can be related to a series of pathological processes that appear 
to be altered in this dysfunction. AD is a complex multifactorial disorder in which protein 
alteration, oxidative stress, immune deregulation, neuronal inflammation, synaptic 
loss[36], defects in neurotransmission, disruption of neural network activity, and reduction 
of energy metabolism [19, 37] are considered triggering factors for neuronal degeneration. 
To increase the complexity of AD, the balance among these may vary from patient to 
patient[38]. Interestingly, the early symptoms of amnesia, if in the absence of any other 
clinical signs of brain injury, suggest that something is intermittently interrupting the 
function of synapses that help to encode new declarative memories, agreeing with the 
hypothesis that Alzheimer’s disease is a synaptic failure[39]. 
Neuroimaging enabled the identification of the areas of the brain that were undergoing 
morphological and volumetric structural changes. The major areas suffering from these 
alterations are the entorhinal cortex and hippocampus, showing some correlation between 
the extent of alteration and cognitive symptoms/disease severity[6, 40]. Despite the vast 
knowledge acquired along the past century, the molecular pathway for AD origin is still 
mostly unknown. 
 
“Aβ and Tau – cause or consequence?” 
Different lines of thinking try to explain the molecular pathogenesis of AD, yet none 
has already been completely proven. Among them, two hypothesis stand out, giving rise 
to long and hard arguments between their supporters. The central foundation of these two 
theories relies on one question: Are amyloid plaques or neurofibrillary tangles the cause 
or a consequence of AD? First of all, the definition of two fundamental terms, and their 
inherent concepts, is necessary to understand this complex pathology. 
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1. Amyloid definition 
The term amyloid (or a so-called amyloid state) was introduced by Virchow, in 1854, to 
denote a macroscopic tissue abnormality that exhibited a positive iodine staining 
reaction[41]. Currently, it is used to sort a class of proteins with a propensity to undergo 
conformational changes and share specific structural traits, resulting in insoluble fibril 
formation[41]. According to the Nomenclature Committee of the International Society of 
Amyloidosis, amyloid consists in extracellular depositions of protein fibrils with 
characteristic appearance in electron microscope, typical X-ray diffraction pattern (β-
sheet)[42], and affinity for thioflavin dyes[43] and Congo red[44] (producing an apple-
green birefringence). On electron microscopy, amyloid consists of rigid, linear, non-
branching, aggregated fibrils that are 7.5 – 10.0 nm in width and of indefinite length[45]. 
The deposition of amyloid fibrils is a 
consequence of the intermolecular 
hydrogen bonding of extended 
polypeptide strands that arise as a 
consequence of protein misfolding[46]. 
Out of curiosity, fewer than 25 amyloid-
forming proteins have been identified 
and associated with a unique clinical 
syndrome, such as: Aβ with AD, 
transthyretin (TTR) with familial 
amyloidotic polyneuropathy (FAP)[47], 
islet amyloid polypeptide (IAPP) with 
diabetes type 2, and prion protein (PrP) 
with the spongiform 
encephalopathies[48]. For the present 
work, we are only interested in amyloid 
deposits composed by Aβ peptide.  
Senile Plaques – Hallmark #1 
To Aβ amyloid deposits (Figure 2) 
was attributed the nomination of senile plaques (SPs), and they can be distinguished in 
different plaques subtypes, including neuritic, diffuse, primitive, compact, cored and 
cotton-wool[14] depending on their composition. Despite of the variety, neuritic and diffuse 
plaques are considered the two major subtypes in AD. Neuritic plaques are constituted by 
Figure 2. Senile plaques and neurofibrillary tangles.  Inferior 
temporal cortex immunolabeled for abundant amyoid plaque 
deposits (A), and abundant neurofibrillary tangles (B) (bar=10 
μm). (Adapted from Bennet et al., 2004)[1]. 
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the 40– and 42–amino acid (aa) β-amyloid (Aβ40 and Aβ42, respectively) peptides, of about 
4 kDa, surrounded by dystrophic neurites (axons and dendrites), microglia (monocyte- or 
macrophage-derived cells that reside in the brain), and reactive astrocytes[49, 50]. Diffuse 
deposits are mainly composed of Aβ42[51]  and lack the neuritic and glial components[52], 
but evolve over time with formation of discrete niduses that eventually become neuritic 
SPs[53]. 
2. APP and Aβ peptide: introducing concepts 
The β-amyloid precursor protein (APP) is a transmembrane receptor (Figure 3) 
expressed ubiquitously in both neuronal cells and extra-neuronal tissues[54]. In humans, 
the APP gene is located in the chromosome 21 and is composed of 18 exons[55]. Three 
major isoforms are expressed by alternative splicing: APP770 (full length), APP751 
(lacking exon 8), and APP695 (lacking exon 7 and exon 8)[56, 57], comprising mRNAs 
ratio of 1:10:20, respectively, in human cortex[54]. It belongs to a highly conserved family 
of type 1 transmembrane glycoproteins that extends also to invertebrate species, 
including the homologous: APL-1 (Caenorhabditis elegans), APPL (Drosophila), appa and 
appb (zebrafish), and APLP1 and APLP2 (in mammals, besides APP)[58]. APP770 and 
APP751 isoforms are expressed in most tissues and contain the Kunitz Protein Inhibitor 
(KPI) domain while APP695 isoform is mostly expressed in neurons and lacks this 
domain[57]. An interesting observation is that AD brain samples show increased levels of 
KPI-containing APP isoforms, thus suggesting that the balance between the KPI- and 
non-KPI-containing isoforms may be an important factor influencing Aβ deposition[59]. 
  
Figure 3. Schematic diagram of the amyloid precursor protein (APP) and its cleavage to give b-amyloid. (a) APP is 
an integral membrane, proteoglycan-like molecule of 700 amino acids (full length isoform); sulphation (SO4), 
phosphorylation (PO4) and carbohydrate attachment (CH2O) sites, the Kunitz-type protease inhibitor domain (KPI) and the 
secretory signal sequence (‘Signal’) are shown. (b) The protein is proteolytically processed by secretases in several 
different pathways. Cleavage of APP at the β and γ sites generates Aβ sequences of 40 or 42 residues (amino acids in 
single-letter code). The most common cleavage by α-secretase precludes Aβ formation. (Chen and Schubert, 2002)[60]. 
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The 4 kDa Aβ peptide, originated by the sequential cleavage of APP[61] (Figure 3), 
was first isolated and sequenced by Glenner and Wong, in 1984[62], and can be found in 
the plasma and cerebrospinal fluid (CSF) of healthy humans and other mammals[63]. It 
was described as a 24 aa peptide but later sequencing revealed that the peptide may 
actually comprise 36-43 aa[64], being the two major species Aβ40 and Aβ42. In healthy 
individuals, these two forms make up 90% and about 10%, respectively, of the Aβ 
peptides that are normally produced by brain cells[49]. Despite the little variation between 
forms, they differ greatly in properties. For example, Aβ42 is more hydrophobic, thus, more 
prone to aggregation (compared to the less hydrophobic Aβ40). In fact, it readily 
aggregates in vitro, being considered the more amyloidogenic and hence pathogenic 
species[65]. 
 
Figure 4. A simplified diagram of some of the principal routes of trafficking of the amyloid precursor protein (APP). 
After synthesis on ribosomes, APP is co-translationally translocated into the endoplasmic reticulum (ER) by its signal 
peptide and trafficks through the secretory pathway to the trans-Golgi network (TGN). A small portion of APP molecules 
reaches the plasma membrane, where the secretase cleavages can occur, generating soluble APP, α and β. Some cell 
surface holoproteins that remain uncleaved can be re-internalized via clathrin-coated pits and vesicles (CCVs) and enter the 
endosomal system. Here, they can be recycled to the cell surface, or enter late endosomes and lysosomes, presumably for 
degradation. Aβ40 can be generated in part during endosomal recycling and released at the surface. Aβ42 can be generated 
in considerable part in ER vesicles, and Golgi vesicles appear to contain both Aβ42 and Aβ40. However, our understanding of 
all of the sites in the cell for Aβ generation remains incomplete. (Adapted from Selkoe, 1998)[63]. 
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3. APP processing 
APP is co-translationally translocated into the endoplasmic reticulum (ER) (Figure 4) 
by its signal peptide and matures through the central secretory pathway, with only a small 
percentage of holoproteins reaching the cell surface[63]. During and after this trafficking 
through the ER, Golgi and trans-Golgi network (TGN), APP suffers specific 
endoproteolytic cleavages[63] that will originate several APP metabolites, among them the 
Aβ peptide. After reaching the membrane surface, APP can still undergo clathrin-mediated 
endocytosis and then rapidly recycle to the surface again[66], during which Aβ can also be 
produced[63]. 
Towards Amyloidogenicity or Non-amyloidogenicity? 
APP processing can originate different metabolites (with different functions) depending 
on the proteolysis pathway initiated. Whether the amyloidogenic or non-amyloidogenic 
pathway is followed (Figure 5) is defined by the protease that initially cleaves the Aβ 
precursor. 
The non-amyloidogenic pathway includes cleavage of APP by α-secretase, a zinc 
metalloproteinase of the ADAM family[57], followed by the action of γ-secretase[56], a 
high molecular weight complex of four proteins: presenilin 1 or 2 (PSEN1, PSEN2), 
nicastrin (NCT), anterior pharynx-defective 1 (APH1), and presenilin enhancer 2 
(PEN2)[31, 67]. The cleavage by the α-secretase at Lys687 abrogates the production of 
Aβ since the cleavage is within the Aβ domain, resulting in the release of a large soluble 
ectodomain of APP called sAPPα (~100 kDa)[57], leaving behind a 83-residue carboxi-
terminal fragment (CTFα, of ~10 kDa[68]). Then, γ-secretase acts in the CTFα, liberating 
the extracellular p3 peptide and the 50 aa APP intracellular domain[64] (AICD, of ~6 
kDa)[69]. 
On the other hand, well suggested by its name, the amyloidogenic pathway 
originates Aβ peptide and consists of two sequential cleavages, first by the β-secretase 
(beta-site APP–cleaving enzyme 1 – BACE-1), and then by γ-secretase[36], after which 
Aβ may first appear in soluble form either within neurons or in the extracellular space[70]. 
The first protease, β-secretase, cleaves APP at Met671, releasing a large soluble 
ectodomain of APP called sAPPβ[71] (similarly to what happens in the non-amyloidogenic 
pathway). The remainder 99 aa CTFβ (of ~13 kDa[68]) is then cleaved by the γ-secretase, 
which occurs in the middle of the membrane and liberates, as said above, the Aβ peptide 
and the AICD[72]. This process generates different species of Aβ with variable 
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hydrophobic C-termini (due to the various proteolysis sites of γ-secretase) (Figure 6) that 
present different propensity to oligomerize[72] and, consequently, to form SPs. As 
previously referred, PSEN1 and PSEN2 mutations are highly correlated with AD: these 
membrane proteins, mainly localized to the endoplasmic reticulum and Golgi, are 
components of the γ-secretase complex, thus AD-linked mutations selectively enhance γ-
secretase cleavage after residue 42 of Aβ[63]. 
 
Figure 5. Processing of Amyloid Precursor Protein. The cleavage by α-secretase, interior to the Aβ sequence, initiates 
non-amyloidogenic processing. A large amyloid precursor protein (sAPPα) ectodomain is released, leaving behind an 83-
residue carboxy-terminal fragment. C83 is then digested by γ-secretase, liberating extracellular p3 and the amyloid 
intracellular domain (AICD). Amyloidogenic processing is initiated by the β-secretase beta-site amyloid precursor protein-
cleaving enzyme 1 (BACE-1), releasing a shorter ectodomain, sAPPβ. The retained C99 is also a γ-secretase substrate, 
generating Aβ and AICD. AICD is a short tail (approximately 50 amino acids) that is released into the cytoplasm after 
cleavage by γ-secretase. AICD is targeted to the nucleus, signaling transcription activation. (Adapted from Querfurth and 
LaFerla, 2010)[64]. 
Figure 6. Various proposed sites of 
intramembrane proteolysis by γ-secretase. 
The amino-acid sequence around the cleavage 
sites of APP is shown (numbers refer to the 
sequence of Aβ; shaded amino acids are in the 
transmembrane domain). γ-secretase cuts its 
substrates several times and thus the cleavage 
sites are referred to as ε, ζ and γ (from the C- to 
N-terminal). The γ-site is variable and can occur 
at least after amino acids 38, 40 and 42. This 
cleavage is highly relevant for the subsequent 
aggregation propensity of Aβ. Some γ-
secretase-modifying drugs shift the cleavage at 
Aβ42 to amino acid 38, and the resultant peptide 
aggregates much less readily. (Adapted from 
Haass and Selkoe, 2007)[72] 
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APP metabolites 
In contrast to Aβ, the sAPPα metabolite has an important role in neuronal plasticity 
and survival[73] and acts as a protector against neuron insults (excitotoxicity and 
metabolic and oxidative insults)[74]. Interestingly, expression of sAPPα is sufficient, by 
itself, to rescue the abnormalities of APP-deficient mice, implying that most of APP’s 
physiological function is influenced by sAPPα levels[75]. Although sAPPβ only differs from 
sAPPα by lacking the Aβ:1-16 region at its carboxyl-terminus, sAPPβ was reported to 
function as a death receptor 6 ligand and to mediate axonal pruning and neuronal cell 
death[57]. The function of the AICD is unclear, nevertheless, it has been shown to 
translocate to the nucleus, forming a transcriptionally active complex with Fe65 and the 
chromatin-remodeling factor Tip60[58]. Concerning the small p3 peptide, despite existing 
evidences of its role as pro-inflammatory agent, its function has not been established[76]. 
This process is the basis of “amyloid cascade hypothesis”, which will be discussed 
forward. 
4. Aβ clearance 
Accumulation of Aβ is intimately related to the progression of neurodegeneration in AD 
and it may be seen as the rate of its generation versus clearance (elimination). This 
elimination process is achieved by two major pathways: proteolytic degradation and 
receptor-mediated transport from the brain[77] (Figure 7). In addition, and as curiosity, 
soluble Aβ can also be removed slowly, via interstitial fluid bulk flow, into the 
bloodstream[78]. However, this is responsible for the clearance of only 10–15% of the 
total Aβ in the brain[78]. 
Proteolytic degradation 
Aβ is degraded by several peptidases, principally two zinc metallo-endopeptidases 
referred to as neprilysin (NEP) and insulin-degrading enzyme (IDE)[77].  
NEP, possesses a catalytic site exposed extracellularly, which makes it a prime 
candidate for peptide degradation at extracellular sites of Aβ deposits[78]. In vivo studies 
revealed that inhibition of NEP protein or disruption of the NEP gene results in a defect in 
degradation and subsequent increased levels of Aβ[79, 80]. This suggests that age-
related decrease of NEP could lead to increased brain concentrations of Aβ, plaque 
formation, and AD[80]. IDE (similar to NEP) hydrolyzes several regulatory peptides, apart  
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Figure 7. Pathways involved in removal of brain Aβ. Soluble Aβ in the parenchyma of the brain can undergo two basic 
fates. It can aggregate into fibrillogenic species that can be ultimately deposited as β amyloid, fostered by interaction with 
heavy metals (zinc, copper, among others). Soluble Aβ can be removed from the brain via two basic pathways: (a) 
enzymatic degradation or (b) receptor-mediated clearance. (a) Soluble Aβ can be degraded by specific peptidases, such as 
IDE and NEP, and, in addition, Aβ can also be internalized and degraded by activated micoglia in the brain. The amyloid 
vaccine has been speculated to promote this activity. (b) In an alternative Aβ clearance pathway, the peptide can be 
transported across the BBB and exported out of the brain into the blood stream either by direct binding to LRP (and P-gp, 
not showed) or by first binding the LRP ligands/Aβ chaperones apoE and α2M. Once Aβ enters the bloodstream, it can 
reenter the brain via the RAGE receptor or be delivered, via chaperone molecules such as apoE or α2M, to peripheral sites 
of degradation, such as liver and kidney. Another proposed mechanism for Aβ clearance is one in which antibodies to β 
amyloid bind Aβ in the blood stream and prevent reentry back into the brain. Green arrows signify pathways that might be 
pharmacologically enhanced, while red arrows and slashed circles indicate pathways that might be blocked as potential 
therapeutic ap proaches for the treatment and prevention of AD. (Adapted from Tanzi et al., 2004)[77] 
from Aβ.  A very convincing evidence of IDE’s role in Aβ degradation came from a study in 
IDE knockout mice that revealed increased levels of Aβ (>50% decrease in Aβ 
degradation) and AICD peptides in the brain[81]. Increasing the evidence, epidemiological 
studies suggest that the gene encoding IDE in chromosome 10q, possesses genetic 
linkage for both LOAD and type 2 diabetes mellitus[78]. 
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Receptor-mediated transport 
 Efflux: LRP1/P-gp combination 
Aβ clearance from brain to blood has to be a two-step process. First it has to pass 
through the abluminal (brain side) and then the luminal (blood side) plasma membranes of 
the brain capillary endothelial cells that comprise the blood-brain barrier (BBB)[82]. The 
first step is suggested to be held by the low-density lipoprotein receptor related protein 1 
(LRP1), while the second still bears some doubts[82]. 
LRP1 is the major efflux transporter of Aβ across the BBB[83]. It is a member of the 
low density lipoprotein (LDL) receptor family and functions both as a multifunctional 
scavenger and signaling receptor, and as transporter and metabolizer of cholesterol and 
ApoE-containing lipoproteins[84]. LRP1 is localized predominantly on the abluminal side 
of the cerebral endothelium and is suggested as the major protein responsible for Aβ 
endocytosis and transcytosis across the BBB[85]. LRP1, in addition to Aβ and ApoE, 
binds several other ligands (approximately 40) such as: α2-Macroglobulin (α2M), tissue 
plasminogen activator (tPA), proteinase-inhibitors, APP, blood coagulation factors, growth 
factors, among others[85]. However, through in vitro ligand-binding affinities assays, LRP1 
was found to preferentially bind Aβ peptides as compared to other ligands[86]. It appears 
genetically linked to AD in epidemiological studies and is negatively regulated by Aβ 
levels[78]. 
P-glycoprotein 1 (P-gp, also known as ATP-binding cassette B1 (ABCB1)) is an ATP-
dependent efflux pump that, as well as mediating the removal of ingested toxic lipophilic 
metabolites[83], was suggested to be also an important (second step) active transporter of 
Aβ[87]. The conjugation of two results: a demonstration of direct interaction between Aβ 
and P-gp, and the post-mortem analyses of AD brain samples showing a negative 
correlation with Aβ deposition[88]; suggest that P-gp in directly involved in the clearance 
of Aβ. Another member of its family, cholesterol efflux regulatory protein (CERP, also 
known as ABCA1), has also been suggested to take part in this process. Contrary to P-gp, 
CERP controls Aβ clearance indirectly, via an ApoE dependent manner, thus enhancing 
its clearance from the brain[87]. 
This suggests that cooperation between LRP1 and P-gp is necessary for the efficient 
efflux of Aβ, thus, LRP1 should not be regarded as the only intervening. 
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 Influx: RAGE-mediated 
The receptor for advanced glycation end products (RAGE), is a multi-ligand and cell 
surface receptor that binds soluble Aβ, and a major transporter of pathophysiologically 
relevant concentrations of plasma Aβ across the BBB[78]. RAGE expression has been 
found to be increased in brain endothelial cells and vascular smooth muscle cells in 
animal models of aging as well as in AD patients[89]. Contrary to LRP1, RAGE expression 
is positively correlated and sustained at an elevated level by excess amounts of Aβ, 
through a positive-feedback mechanism[78]. 
“Sink” hypothesis 
The continuous removal of Aβ from the brain, blood and organs is essential for the 
regulation of Aβ brain levels. At the moment, a three-step process, dubbed as the “sink” 
hypothesis, is proposed to explain Aβ homeostasis. (1) Aβ binding to LRP1 at the cell 
membrane initiates rapid Aβ clearance across the BBB into the blood in vivo, followed by 
(2) circulating plasma soluble LRP1 (peripheral “sink” for brain Aβ) binding to and 
sequestering (>70% of) free Aβ in plasma, thus promoting continuous removal of Aβ from 
brain[89]. sLRP1 is the truncated extracellular domain of LRP1, after β-secretase 
cleavage of its β-chain[85]. Finally, (3) LRP1 localized to hepatic cells binds to and 
systemically clears circulating Aβ. In addition to the liver, sLRP1-Aβ complexes and free 
Aβ are also eliminated through the kidneys[89]. Sagare et al. showed that in AD patients 
the levels of sLRP1 were lower than in controls, plus, there was a huge increase in 
oxidized sLRP1 with very little affinity towards Aβ[86]. This will increase the Aβ free 
fraction promoting the influx from blood to brain. 
5. Tau protein: introducing concepts 
Tau protein was discovered in 1975 by the group of Marc W. Kirschener and belongs 
to the microtubule-associated protein (MAP) family[90, 91]. It is manly considered an 
axonal protein expressed in mature neurons[92] and defined as an essential protein for 
microtubules assembly and stability[90] and vesicle transport[64]. Tau can be found in 
many animal species such as Caenorhabditis elegans, Drosophila, goldfish, bullfrog, 
rodents, and human[93]. It is present as a single-copy gene (over 100kb)[94], localized on 
the long arm of chromosome 17q21[95] (MAPT gene[32]), and contain 16 exons (three of 
which are never present in mRNA of brain tissue – 4A, 6 and 8)[96]. In the central nervous 
system, alternative splicing of tau primary transcript generates six isoforms with an 
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apparent molecular weight between 60 and 74 kDa[97] and a natively unfolded 
conformation[98]. 
Tau – just medium phosphorylated 
Tau is a component of microtubules, which represent the internal support structures 
for transport of nutrients, vesicles, mitochondria and chromosomes from the cell body to 
the ends of the axon and back[99]. It binds to microtubules through repetitive regions in 
their C-terminal part encoded by exons 9-12[93] and is considered a highly soluble protein 
that shows hardly any tendency to assemble under physiological conditions[100]. The 
different states of tau phosphorylation result from the activity of specific kinases and 
phosphatases[93], thus, an imbalance between these two classes of proteins will affect 
tau’s biological function. In a hyperphosphorylated state, tau changes its native 
conformation and loses its affinity toward microtubules[101], thus being released in a 
soluble form[102]. Then, newly soluble tau proteins can be targeted for post-translational  
modifications (not necessarily just phosphorylation) that directly or indirectly alter tau 
conformation, promoting tau aggregation and paired helical filaments (PHFs) 
formation[97]. The longest form of tau (441 aa) possesses 85 putative phosphorylation 
sites (Figure 8)[103] (serine, threonine and tyrosine residues), which are available to 
numerous kinases, such as casein kinase 1 (CK1 – considered the major kinase of tau 
due to the)[97, 104], mitogen-acivated protein kinases (MAPKs), glycogen synthase 
kinase 3β (GSK3β), and cyclin-dependent kinase 5 (CDK5)[105]. Abnormal 
phosphorylation is not the only cause of tau’s conformational change. Mutant tau proteins 
may also have diminish affinity for microtubules and promote, consequently, tau 
aggregation into PHFs, specially when this occurs inside the microtubule-binding 
domain[100]. More than 30 mutations of tau gene have been described, nevertheless, 
tau’s mutations are not observed in AD[64]. Other mechanisms that promote tau 
aggregation have been proposed to involve several posttranslational modifications (such 
as ubiquitination, glycation, glycosylation, and transglutamination), the neuronal redox 
potential and the presence of cofactors (ApoE, and aluminium)[93].   
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Figure 8. Tau phosphorylation sites. Tau phosphorylation sites found in AD brains (in red), those found in normal brain (in 
green) and those present both in normal and AD brains (in blue) are indicated according to the longest tau isoform tau. 
Putative phosphorylation sites that have not yet been proven to be phophorylated in vitro or in vivo (in black). (Adapted from 
Martin et al., 2011)[97] 
Neurofibrillary tangles: Hallmark #2 
Neurofibrillary tangles (NFTs) are filamentous inclusions (intracellular lesions), 
preferentially observed in pyramidal neurons, composed of filamentous aggregates of 
abnormally hyperphosphorylated microtubule-associated protein tau[64, 106]. NFTS, are 
constituted by PHFs and by a minor class that does not exhibit the marked modulation in 
width of PHFs[107] – straight filaments (SFs). Like SPs, NFTs are hallmarks of AD and 
responsible for other neurodegenerative disorders termed tauopathies[108] (e.g. Pick’s 
disease, progressive supranuclear palsy, amyotrophic lateral sclerosis/parkinsonism–
dementia complex of Guam, and some frontotemporal dementias)[92, 93].  
Resuming to the explanation of AD pathogenesis, various hypotheses have been 
proposed with very different and plausible molecular mechanism, backing it up. Two 
hypotheses stand out, the “amyloid cascade hypothesis” and a so-called “tau and tangle 
hypothesis”, very likely due to the fact that they are centered in the two hallmarks of AD.  
6. Amyloid cascade hypothesis 
First of all, it is of great importance to mention that APP processing is a normal 
metabolic event and that Aβ  is a normal product of cellular metabolism throughout life 
and circulates as a soluble peptide in biological fluids[109]. Plus, Aβ deposition can also 
be found in the brain of non-demented elderly people. 
The most persuasive theory is the “amyloid cascade hypothesis”[110] (Figure 5) and it 
suggests that amyloid deposition is the first step of a cascade of processes that ultimately 
culminate in disease[1, 25]. More concretely, it is based on the effects that the highly 
insoluble forms of Aβ peptide (as SPs or as toxic oligomers) have in terms of 
neurotoxicity, due to a dysregulation in APP processing or Aβ clearance, early in the 
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disease process[111]. It was first suggested that this dysregulation would increase the 
Aβ42/Aβ40 ratio, in other words, promote the production of the most neurotoxic form (Aβ42). 
This would lead to aggregation and to SPs’ formation, which in turn would be responsible 
for the subsequent pathology (including tau aggregation, phosphorylation, neuronal 
attrition and clinical dementia)[111]. Nonetheless, amyloid fibrils are not the only form of 
Aβ possible to observe. Various species, including monomers, oligomers, and protofibrils 
(usually shorter and thinner than amyloid fibrils)[112], with different characteristics, are 
gaining interest as to explain the toxic effects of Aβ. The relationship between SPs and 
clinical manifestations or neurodegenerative changes is quite controversial. Thus, more 
recently, the attention has been deviated from the harmfull effects caused by SPs, giving 
prevalence to the toxic Aβ oligomer hypothesis. Perhaps due to a greater capacity for 
diffusion and larger collective surface area for interacting with neurones and glial cells[61]. 
Some suggest that Aβ toxicity functions in a plaque-independent manner[113], stating that 
oligomeric intermediates present higher toxicity to the cell and, in addition, this is not 
related to a specific prefibrillar aggregate (dimer, trimer, and so on) but rather to the 
propensity that each species has to grow and undergo fibril formation[114]. 
Several observations consistent with the amyloid cascade hypothesis are continuously 
being found, e.g. intraneuronal accumulation of Aβ oligomers can activate signalling 
pathways which cause tau hyperphosphorylation[61]. This particular discovery 
strengthens the hypothesis on one hand, and on the other discredits the “tau and tangle 
hypothesis” (discussed forward). Other serve as supplement for this hypothesis and can 
be grouped together as Aβ-related hypotheses. It is the case of biometals (Zn(II) and 
Cu(II)) involvement with Aβ, microglia-derived toxicity, or membrane permeabilization by 
Aβ oligomers. Concerning the first, several contradictions in the application of the amyloid 
hypothesis can be removed by considering the role of redox-active metals in plaques as 
primary toxic agents and biometals as the trigger of Aβ fibrillization, in the case of 
sporadic AD[115]. As for the second, the inflammation hypothesis states that active 
phagocytic microglia, triggered by Aβ oligomers, is the primary cause of early toxicity[61]. 
However, the role of the different Aβ forms inducing the microglial phagocytosis, 
generation of oxidative stress, and inflammatory response remain unclear[116]. Finally, 
membrane permeabilization by amyloid oligomers (after formation of discrete pores or 
single channels – “channel hypothesis”)[43], leading to an increasing in intracellular 
calcium concentration, has been proposed as the primary mechanism of 
pathogenesis[117]. Nevertheless, there is some disagreement as to the mechanism by 
which amyloid oligomers increase intracellular calcium[43]. 
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Karl Herrup, in 2010, proposed a new model for AD build on a 3 key event: (1) a 
precipitating injury (head trauma, vascular events, illness or stress could initiate a 
protective response) that may not cease due to age-related failure of the normal 
homeostatic mechanisms), triggers (2) chronic inflammation, which in turn leads to (3) 
major physiologic shift in neurons[29]. 
A more consensual vision about Aβ is that it possesses a dual role: a neurotrophic and 
a neuronal degeneration action (if in high concentrations) in mature neurons. This is not a 
theory too difficult to accept since in Nature everything that is exaggerated brings some 
degree of harm. Its neuroprotective role was suggested to act against excitotoxic death by 
activating the phosphatidylinositol-3-kinase (PI-3K) pathway, serving as a double 
prooxidant/antioxidant and shown to bind and remove harmful substances by blocking 
them in plaques[118]. 
There are still some that defend a more controversial hypothesis, the “alternate 
hypothesis”, which opposes the amyloid cascade hypothesis by proposing that Aβ is not 
as a harbinger of death but rather a protective response to neuronal insult[119]. Despite 
all the advances made, the source of Aβ toxicity still remains elusive. 
7. Tau and tangle hypothesis 
“Tauists”, defend a collection of related ideas that maintain the primacy of NFTs 
formation as the AD-causing event, which Mudher and Lovestone designated as the “tau 
and tangle hypothesis” (Figure 9)[111]. It has emerged due to solid evidence that SPs do 
not account for the complex pathophysiology of AD[38]. It argues that in AD the normal 
role of tau is impaired and that NFTs accumulate to occupy much of the neuron and 
apparently result in neuronal death, as extracellular tangles in the shape of neurons are 
abundant in late stages of disease[111]. Maccioni et al, postulated a much more 
embracing tau hypothesis, in which, a series of damage signals (Aβ oligomers, oxygen 
free radicals, iron overload, cholesterol levels in neuronal rafts, LDL species and 
homocysteine, among other) trigger, by innate immunity, the activation of microglial cells 
with the consequent release of pro-inflammatory cytokines that modify neuronal behavior 
through anomalous signaling cascades, which finally, promote tau 
hyperphosphorylation[38]. As described in the tau section, hyperphosphorylation leads to 
tau oligomerization and production of NFTs that, after neuronal death, are released to the 
extracellular environment (“ghost tangles”, remaining characteristically stable[105]), 
contributing to activation of microglial cells and stimulating the deleterious cycle, leading 
to progressive neuronal degeneration[38]. 
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Figure 9. Tau Structure and Function. Normal phosphorylation of tau occurs on serine and threonine residues. These 
amino acids can be phosphorylated by a series of kinases, such as: glycogen synthetase kinase 3 (GSK-3β), cyclin-
dependent kinase (cdk5) and its activator subunit p25 (shown), mitogen-activated protein kinase (MAPK), Akt, Fyn, and 
protein kinase A (PKA) (not shown). Tau binding promotes microtubule assembly and stability. Excessive phosphorylation of 
tau leads to decreased tau binding to microtubules, increasing free tau, which, under the appropriate conditions, will self-
aggregate to form insoluble PHFs (paired helical filaments). Loss of tau binding is predicted to result in loss of microtubule 
function. All this process leads to neuronal death, which might result in dementia. (Adapted from Querfurth and LaFerla, 
2010)[64]. 
The degree of tau phosphorylation in the AD brain is reasonably well correlated with 
the severity of AD symptoms. However, fetal tau, a much more phosphorylated form of tau 
than adult tau, does not induce AD-like pathology. In summary, there is no direct evidence 
for the neurotoxicity of hyperphosphorylated tau[105] (as in the case of Aβ toxicity). 
Whilst discovering what and how is causing this complex AD pathology is 
fundamental, the ultimate goal for every scientist is finding the cure, or if not possible, 
finding a suitable temporary treatment. 
 
  
FCUP/ICBAS  32 
                  Introduction 
Finding the treatment 
Due to the complexity of AD, a vast number of targets and pathways may be chosen 
to intervene. Cholinergic degradation inhibitors, immunotherapy, secretase inhibitors, anti-
inflammatory drugs, tau- and Aβ-deposition interfering drugs, are a few examples of huge 
classes of drugs that are being tested at the moment[120].  A few options for therapies will 
be listed next, however, it is important to notice that they only aim to treat symptoms and 
not the cause of the disease. 
The first drugs developed for AD, acetylcholinesterase inhibitors (AchEI), aimed at  
increasing acetylcholine levels, previously demonstrated to be reduced in AD [7]. 
Currently, 5 drugs (FDA approved) are used for the “treatment” of AD in the initial stages: 
4 AchEI (Donepezil, Rivastigmine, Galantamine and Tacrine) and 1 NMDA receptor 
antagonist (Memantine) (http://www.alzforum.org). As referred above, they are not 
effective, so other targets must be searched. 
The first study to prove target engagement by a disease-modifying drug in living 
humans was reported by Rinne and colleagues, in 2010, using the monoclonal anti-Aβ 
antibody bapineuzumab[31, 121]. It revealed a reduction of fibrillar amyloid in the brain of 
AD individuals, but did not improve cognition or function[122]. Crenezumab is another 
antibody being used in pre-symptomatic treatment trials of Colombian mutant PSEN1 
kindred[31]. These are just two examples of an immense list of antibodies that are being 
studied at the moment. Intravenous immunoglobulins (IVIG) have been proposed as 
potential treatment based on the hypothesis that IVIG contains naturally occurring 
antibodies that specifically promote clearance of Aβ peptides from the brain[123]. 
Secretase modulators[31], tau deposition modulators (e.g., methylene blue[64]) and 
molecules addressing oxidative damage[7] are also potential drugs under study. 
Unfortunately, not everyone responds positively to drugs that halt the progression of the 
disease and, when they do, the protective effect runs off over time. Recently, the “return” 
of electric shock therapy – deep brain stimulation – by the group of Dr Lozano, from 
Toronto, gave some hope to the society[124]. Not only did it stop the progression of the 
disease as also, in less affected patients, suggests a likely improvement in condition[18, 
19]. Nevertheless, further work of this approach will be necessary. 
A general recommended therapy is Diet and Lifestyle, so that cardiovascular risk 
factors can be controlled. This will decrease cerebrovascular events, which, in turn, will 
lead to a reduction in both vascular dementia and the poorly understood contribution of 
vasculopathy to AD[31]. 
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Since no effective treatment has been developed, the best scenario is an early stage 
intervention. One common expression can be used to define the treatment approach in 
AD (and the rest of diseases): the sooner, the better, meaning that the sooner you 
discover the disease, the greater the odds of treating it. Thus, the search for proper 
(highly sensitive and specific) biomarkers is on constant demand, allowing a more 
effective and early stage intervention. 
 
Diagnosis and Biomarkers 
The search for early AD biomarkers has been highly targeted over the last years, as 
investigators believe that the generation of an effective treatment for AD is only possible if 
the disease is detected at very early stages. 
According to Phelps and colleagues, in 1998, the sensitivity of the clinical diagnosis of 
AD is 93% and the specificity is 55% (which varies with age)[125]. It is a high value but 
when used in combination with other characterizing techniques (as biomarkers) it is 
possible to predict/diagnose AD with a greater confidence. By definition, and according to 
the International Programme on Chemical Safety biomarker is “any substance, structure, 
or process that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease”[126]. In AD, biomarkers are used to early diagnose the 
disease, by predicting who is going to develop AD from mild cognitive impairment 
(MCI)[127]. 
Neuroimaging, has recently been given some evidence in diagnosis (with 
improvement in PET and MRI spectroscopy resolution) due to the possibility of using 
specific tracers, such as a derivate of thioflavin T that crosses the BBB and binds 
selectively to Aβ (C11-labeled Pittsburgh Compound B – PiB[128]) that allow the 
identification of amyloid deposition in the brain in vivo [6] . In 2002, Klunk and colleagues 
reported a “definitive” diagnosis technique for AD – brain amyloid imaging (BAI) – using 
the PiB compound[128]. By 2010, the combination of increased BAI signal, low CSF Aβ42, 
and high CSF tau in a subject with dementia was recognized as diagnostic for AD, and 
patients with MCI and appropriate BAI and CSF profiles could be predicted to progress to 
frank dementia with high degree of confidence[31]. However, further studies showed the 
existence of some conflicting reports, since it was not always possible to differentiate 
symptomatic AD from asymptomatic controls with amyloid plaques[14]. The combination 
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of neuroimaging and biomarker profile increases the predictive value of AD diagnosis and 
may lead to a correct characterization of persons at risk, prior to the development of 
clinical symptoms[6]. 
There has been an increase in the search for solid AD biomarkers, starting with those 
who seem to be altered in this condition when compared to normality. Hansson and group 
stated that the combination of CSF total-tau, phospho-tau and Aβ42 yielded good 
sensitivity and specificity for detection of AD in patients with MCI[40, 127]. More recently, 
a model based on Aβ42 and total-tau levels was developed that could accurately 
discriminate AD from controls by means of a discrimination line. After autopsy validation 
the model revealed a sensitivity of 100% and specificity of 91%[129]. Another obvious 
candidate is the major susceptibility gene for AD, ApoE-ε4. When grouped on the basis of 
CSF tau and Aβ markers, the association of ApoE-ε4 with AD was twice as strong as 
compared to when classifying patients according to clinical status[130]. CSF BACE-1 (β-
secretase) is also being studied, demonstrating that (despite the small number of 
subjects) AD patients had increased BACE-1 activity compared with non-
demented[131].  Levels of CSF sAPPβ, when combined with CSF tau, have also been 
reported to be useful in predicting cognitive decline in MCI cohorts[132]. Transthyretin 
(TTR) in CSF has also been proposed as a biomarker and revealed a significant (and 
selective for AD) negative correlation between TTR CSF levels and disease severity in 
AD[133]. Other studies came to contradict this idea suggesting that TTR potential as 
biomarker raises some doubt since its levels appear to fluctuate substantially within a 
single individual over a 2-week interval[132].  
CSF biomarkers are very promising, although its collection is invasive and thus difficult 
to be a regular procedure in AD diagnosis. Plasma-derived biomarkers, such as Aβ42/Aβ40 
ratio may also be useful in the identification of increased risk for developing MCI or 
AD[134]. Other are under investigation, and for instance, TTR plasma levels also showed 
a negative correlation between with AD [27, 135], supporting the observations reported for 
CSF. 
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Transthyretin – FAP and then AD  
1. From component X to transthyretin  
TTR was described for the first time by Seibert and Nelson, in 1942, as an X 
component “which is slightly more mobile than albumin”[136], and thus called prealbumin. 
Its current name is derived from its primary function, transport of thyroxine (T4) and 
retinol, through the binding of retinol binding protein (RBP)[137]. TTR is a 55 kDa 
homotetrameric protein synthesized mainly by the liver and the choroid plexus[138] 
(corresponding to  20% of total protein synthesized[139]) and secreted into plasma and 
CSF, respectively. TTR is a single-copy gene mapped in chromosome 18 and its mRNA 
codifies a 147 aa peptide, corresponding to the TTR-monomer[140]. It is an evolutionary 
conserved protein and it is found in many vertebrates’ species[140] The four monomers 
within a TTR tetramer, form an open channel where T4 binds (Figure 10) while retinol 
interacts with only one of the dimers, at the surface[27]. 
Yet another TTR function was discovered: Liz et al. also established TTR as a cryptic 
protease of apoliprotein A1 (ApoA-1)[141] and later showed that TTR may affect HDL 
biology and the development of atherosclerosis by reducing cholesterol efflux and 
increasing the apoA-I amyloidogenic potential[142]. Thus, the possible protease role of 
TTR in the proven interaction with Aβ was addressed and it was observed that TTR was, 
indeed, able to proteolytically process Aβ in vitro [137]. In addition, cleaved Aβ peptides 
showed lower amyloidogenic potential than the full length counterpart[137]. 
2. TTR as a disease factor 
TTR is the key protein in familial amyloidotic polineuropathy (FAP), firstly described as 
“peculiar form of peripheral neuropathy”, in 1952 by the Portuguese professor Corino de 
Andrade[143], and associated to a deposition of TTR protein in 1978, by Costa et al.[144]. 
FAP is a hereditary autosomal dominant neurodegenerative disorder characterized by the 
presence of amyloid fibrils (Figure 10), especially through the peripheral nervous system, 
that leads to organ dysfunction and ultimately, death[145]. Several TTR mutations (over 
100) have been related to provoke amyloid deposition and disease[146], the most 
frequent being the substitution of a valine residue for a methionine at position 30 
(V30M)[147]. Other mutations should also be referred: T119M (substitution of threonine 
for methionine at position 119), a non-pathogenic variant presenting high binding affinity 
for T4 as compared to normal TTR[148]; and L55P and Y78F (substitution of leucine for 
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proline at position 55 and tyrosine for phenylalanine at position 78, respectively), two very 
aggressive pathogenic mutations that alter significantly TTR conformation[149, 150]. 
 
Figure 10. Transthyretin (TTR) structure and amyloidogenesis cascade. TTR is an homotetramer, with each monomer 
bearing 147 amino acid residues. The 4 monomers together form an open channel where T4 can bind. For amyloidogenesis 
to occur, the TTR tetramer must first dissociate into four folded monomers and undergo partial denaturation. These pieces 
then subsequently misassemble into a variety of aggregate structures including toxic amyloid fibrils. (Adapted from 
http://www.scripps.edu/newsandviews/e_20110905/diagram.html) 
It is believed that the amyloidogenic potential of the TTR variants is related to a 
decrease in tetrameric stability [151] and that the dissociation of the tetramer into 
monomers is the basis of a series of events that lead to the formation of TTR amyloid 
[152, 153]. Thus, TTR stabilization has been proposed as a key step for the inhibition of 
TTR fibril formation and has been the basis for FAP therapeutic strategies [154, 155]. 
Such stabilization can be achieved through the use of small compounds sharing molecular 
structural similarities with T4, mostly belonging to the NSAIDs and binding in the T4 central 
binding channel [156-160]. 
3. TTR as a protective molecule in AD 
The first report that associates TTR to Aβ and AD in the context of a protective 
molecule is from Schwarzman et al. which describes the capacity of normal CSF to inhibit 
amyloid formation[161]. Prior to this finding, TTR was found associated to SPs, NFTs and 
microangiopathic lesions[162]. Although it was already known that other proteins such as 
TTR monomersT4 binding pocket
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ApoE, ApoJ, gelsolin[163] and APP are able to sequester Aβ, contributing for the 
prevention of AD, Schwarzman and colleagues concluded that TTR was the major Aβ 
binding protein in the CSF[161]; TTR was also able to decrease the aggregation state of 
the peptide and to avoid its toxicity. The sequestration hypothesis was raised, suggesting 
that normally produced Aβ is sequestered by certain extracellular proteins, thereby 
preventing amyloid formation and Aβ cytotoxicity; when sequestration fails amyloid 
formation occurs[164]. The observation that TTR is reduced in the CSF of AD patients 
further supported the idea of a TTR protective role in this pathology[165]. Mammalian 
models have been used to mimic AD features but were never completely successful: AD 
transgenic mice did not show neurofibrillary tangles (NFTs) and demonstrate little or no 
neuronal cell loss[166-171]. However, in some of the models, animals showed increased 
TTR expression in the hippocampus; TTR was then described to be a survival gene[171] 
and although this work is controversial because TTR expression is thought to be confined 
to the choroid plexus and meninges (in the case of the brain), authors further showed that 
when a chronic infusion of an antibody against TTR was applied into the hippocampus of 
mice expressing human APP, an increase of Aβ, tau phosphorylation, neuronal loss and 
apoptosis was observed[172]. Underlying these observations is, according to authors, 
sAPPα that leads to increased expression of protective genes, such as TTR, to confer 
neuroprotection[172]. Other studies, using transgenic APP mice hemizygous for 
endogenous TTR showed accelerated Aβ deposition[67], while double transgenic mice for 
APP and TTR presented lower deposition[173]. However, in other models, TTR was 
described to have the opposite effect and was associated with increased vascular Aβ 
deposition[174]. More recently, Oliveira et al, reported findings on an APP/PSEN 
transgenic mouse model in different TTR backgrounds. In this study, it was stated that 
mice with genetic reduction of TTR showed increased Aβ brain levels, and that higher Aβ 
deposition was found in females, compared to males[175]. This work provided evidence 
for a gender-associated modulation of brain Aβ levels and brain sex steroid hormones by 
TTR, and suggests that reduced levels of brain testosterone and 17-estradiol in female 
mice with TTR genetic reduction might underlie their increased AD-like 
neuropathology[175]. 
Regarding the nature of TTR/Aβ interaction, different researchers confirmed TTR 
binding to Aβ[176-178], not only to the monomer but also to Aβ oligomers and fibrils, 
raising the hypothesis that TTR may be involved in the formation of senile plaques[137]; 
TTR was also able to inhibit and to disrupt Aβ fibrils. However, which TTR conformation 
binds Aβ peptide is still controversial. Du and Murphy claim that Aβ monomers bind more 
to TTR monomers than to TTR tetramers[179]; in this work, studies performed with WT 
TTR, T119M TTR and a double mutant (F87M/L110M TTR), which is a stable monomer 
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but a non-natural occurring mutation, authors showed that TTR tetramers interact 
preferably with Aβ aggregates rather than Aβ monomers enhancing Aβ aggregation, 
whereas TTR monomers arrest Aβ aggregate growth. Although interesting from a 
scientific point of view, the existence of functional biological active TTR monomers in vivo 
is far from established. Other studies indicated that amyloidogenic and unstable TTR 
mutants bind poorly to Aβ peptide [178, 180], suggesting that this interaction depends on 
the presence of the TTR tetramer. Very recently, genetic stabilization of TTR, through the 
presence of the T119M allele, which renders a more stable tetramer, has been associated 
with decreased risk of cerebrovascular disease and with increased life expectancy in the 
general population [181], further demonstrating the importance of the TTR tetramer in the 
protein biological activity.  
The discussion on the TTR interaction with Aβ and consequent inhibition of 
aggregation and toxicity reduction raised the hypothesis that mutations in the TTR gene or 
conformational changes in the protein induced by aging, could affect the sequestration 
properties. A studied was conducted with the aim of identifying mutations in the TTR gene 
in the AD population but no correlation was found[138]. More recently, polymorphisms in 
the TTR gene were associated to hippocampal atrophy although the study could not 
associate this alteration to AD[182]. Nevertheless, destabilization of the protein may result 
from other events, such as metal ions concentration and interaction with other proteins.  
Supporting the hypothesis that TTR might be destabilized in AD is, on one hand, the 
observation that TTR is early decreased in CSF and plasma of MCI and AD patients, and 
on the other hand, the lower levels of T4 transported by TTR in these groups of 
patients[27], raising the hypothesis that TTR destabilization in AD accelerates its 
clearance, thus explaining the lower levels found. Moreover, in vitro, it is possible to 
restore the ability of TTR amyloidogenic/destabilized mutations to bind to Aβ peptide 
through the use of NSAIDs[183]. Importantly, in vivo administration of iododiflunisal (IDIF), 
one of the drugs shown to strengthen TTR/Aβ interaction, to APP/PSEN transgenic 
female mice in a TTR hemizygous background (model characterized and described by 
Oliveira and colleagues) resulted in decreased Aβ brain levels and amyloid burden, 
amelioration of the cognitive function and lower Aβ plasma levels[184]. This consolidated 
the notion that TTR stabilization is an important factor in TTR protection in AD, and 
suggested that TTR promoted Aβ clearance from the brain and from the periphery [184]. 
Although a growing body of evidence suggests TTR as an important modulator of AD 
pathogenesis, the mechanism underlying the effects described in the literature is 
incompletely understood; proteolytic degradation of the peptide, sequestration and 
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promotion of its clearance either by promoting its efflux from the brain or its uptake by the 
liver, influence in APP processing, and the effect of sex hormones have already been 
hypothesized and need to be further explored. It is also possible that TTR protection in AD 
is also conferred by interference in other pathways/molecules known to be altered in AD, 
such as APP trafficking and synaptic formation, although not yet addressed. In this line of 
thoughts, the experimental work presented in the next sections aimed at investigating the 
behavior of sortilin and synaptophysin, in AD transgenic mice in different TTR 
backgrounds. The above mentioned proteins will be next described, and have been 
proved to affect APP/Aβ circulating levels and neurotransmitter liberation, respectively. In 
addition, and because it relates to APP/Aβ levels, we also evaluated APP expression and 
processing. 
 
Sortilin and Synaptophysin in AD 
1. Sortilin 
Sortilin (Sort1) is a member of the recently discovered family of Vps10p-domain 
receptors (of approximately 94 kDa)[185], and is expressed in neurons of the central and 
the peripheral nervous system, but also in extra-neuronal tissues including liver and 
fat[186]. It is an essential component for transmitting pro-neurotrophin–dependent death 
signals, and thus promotes apoptosis[187]. Agreeing with the latter, an important role of 
Sort1 in neurodegenerative disease has been proposed, by Al-Shawi et al., due to the 
observation of an age-related increase in its expression levels. Increased Sort1 levels, 
combined with also increased levels of proNGF (uncleaved precursor form of the nerve 
growth factor protein), suggest an influence of Sort1 in neuronal atrophy and cell death, in 
their older mice model[188]. After analysis, the authors observed no differences in Sort1 
expression between AD patients and age-matched controls, however, this results show 
that the role of Sort1 in aging should not be despised[188]. Another group has shown, in 
their analysis of AD post-mortem brain tissue, increased levels of Sort1 (compared to 
controls), and suggested a possible role in the development of AD-related pathological 
changes[189]. Then, Sort1 was shown to be a binding protein of APP, and so, its 
influence in the evolution of AD pathogenesis, positive or negative, started being 
investigated. 
Recently, more precisely in January of 2013, two interesting papers were published by 
the same journal. Gustafsen et al., suggested the role of Sort1 as a sorting protein in APP 
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processing. They were able to observe, in vitro, that when Sort1 was decreased, the 
levels of sAPPα were also decreased, suggesting an involvement in APP processing[190]. 
Thus, the proposed interaction of Sort1 with APP, in neurites, promotes α-secretase 
cleavage of APP (inhibiting Aβ production), and influences both production and cellular 
uptake of soluble forms of APP (leading to lysosomal degradation)[190]. The authors also 
commented that the previous findings from Finan et al., suggesting an increase in sortilin 
levels in AD patients, may be due to the use of a C-terminal tagging, which can affect the 
subcellular localization of Sort1. In the other publication, Carlo et al. denied the previous 
hypothesis and proposed Sort1 as a neuronal ApoE receptor, constituting a major 
endocytic pathway for clearance of ApoE/Aβ complexes[186]. Carlo’s group observed, 
using ApoE- and Sort1-deficient mouse models, that the lack of receptor expression in 
mice resulted in accumulation of ApoE and Aβ in the brain, with aggravated plaque 
burden[186]. Thus, these two groups propose a negative correlation of Sort1 and AD 
progression. 
A relationship between Sort1 and AD has been quite established, nonetheless, the 
exact mechanism underlying this involvement is not fully resolved, thus yielding distinct, 
and even sometimes contradictory, hypotheses. 
2. Synaptophysin  
Synaptophysin (Syp), a 38 kDa integral membrane protein, member of the MARVEL 
(MAL and related proteins for vesicle trafficking and membrane link)-domain family[191], 
is the most abundant integral synaptic vesicle protein and, therefore, is often measured in 
attempts to quantify synapses[192]. When bond to synaptobrevin (a protein of the SNARE 
complex), Syp inhibits the binding of the latter to SNARE complex, thus preventing the 
SNARE assembly and vesicle fusion[192, 193] (Figure 11). Since AD is characterized by 
an accentuated synaptic loss, the analysis of Syp’s expression and behavior in AD was 
accessed by several groups. Ishibashi et al. observed that synaptophysin was more 
abundant in AD brain cortex than in controls, but showed a somewhat irregular pattern of 
staining, since a marked decrease was observed in foci where oligomer Aβ 
accumulated[194], leading to loss of normal synaptic functions. Another group revealed a 
link between Aβ42 accumulation and loss of synaptophysin in a transgenic AD mouse 
model, however the expression of Syp in their AD model was decreased, compared to 
control littermates[195], opposing the results from Ishibashi and group. Other agreeing 
studies reveal reduced average levels of Syp in human hippocampus, when comparing 
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AD to control samples, and a correlation between Syp decreased levels and cognitive 
decline in AD[196]. 
 
 
Figure 11. Synaptophysin involvement in vesicle fusion.  Synaptophysin/synaptobrevin complex binds with syntaxin on 
the plasma membrane and forms a fusion pore. Then the tight formation of the SNARE complex disassociates 
synaptobrevin from sinaptophysin, thus weakening the synaptophysin complex and allowing the vesicle to fully fuse. 
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Objectives 
The aim of this study was the search for early TTR-related biomarkers in a transgenic 
mouse model, constituted by AD/TTR+/+ and AD/TTR+/- (bearing two copies of TTR and 
one copy of TTR, respectively) 3- and 7-months-old mice, by means of Western Blot 
analysis. For that we investigated: 
(1) sortilin expression; 
(2) synaptophysin expression; 
(3) APP expression, through evaluation of: 
i. APPfull length 
(4) APP processing, through evaluation of: 
i. CTFs levels 
ii. sAPP levels 
(5) the influence of age in our mouse model, and in the expression of the above 
mentioned proteins. 
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Material and methods 
Animals 
The mouse model AβPPswe/PSEN1A246E/TTR used in this study was established 
and characterized in the Molecular Neurobiology Laboratory at IBMC, Porto. The colony 
was generated by crossing AβPPswe/PSEN1A246E transgenic mice[197] (B6/C3H 
background), purchased from The Jackson Laboratory, with TTR-null mice (TTR-/-) 
(SV129 background)[198] as previously described[175]. Thus, we were able to generate 
AβPPswe/PSEN1A246E/TTR+/+ (carrying 2 copies of the TTR gene), 
AβPPswe/PSEN1A246E/TTR+/- (carrying only one copy of the TTR gene) and 
AβPPswe/PSEN1A246E/TTR-/- (without TTR), hereafter referred to as AD/TTR+/+, 
AD/TTR+/- and AD/TTR-/-, respectively. Animals were housed in a controlled environment 
(12-h light/dark cycle; temperature, 22±2°C; humidity, 45-65%), with freely available food 
and water. All procedures involving animals were carried out in accordance with National 
and European Union Guidelines for the care and handling of laboratory animals. 
In this study, we used two groups of cohorts of littermates. One group was composed 
by 3 months old male and female mice, as follow: 
3 male and 3 female AD/TTR+/+ mice;  
3 male and 3 female AD/TTR+/- mice;  
3 male and 2 female AD/TTR-/- mice. 
The other group was composed by 7 month-old female mice, that underwent IDIF 
administration in a previous study[184]: 
7 AD/TTR+/+ control (not submitted to treatment) mice;  
7 AD/TTR+/+ treated (with IDIF drug) mice;  
8 AD/TTR+/- control mice;  
9 AD/TTR+/- treated mice;  
3 AD/TTR-/- control mice. 
These mice started IDIF treatment at the age of 5 months, before the onset of 
deposition, which lasted for 2 months and thus animals were sacrificed at 7 months of 
age, after the start of Aβ deposition. With regard to this group of mice, brain tissue 
homogenized in Tris Buffer Saline (TBS) and frozen at -80 ºC was already available in the 
laboratory. 
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Tissue Processing 
Animals were sacrificed following anesthesia with a mixture of ketamine (75mg/kg) 
and medetomidine (1mg/kg) administrated by intraperitoneal injection. Efforts were made 
to minimize pain and distress; all animal experiments were carried out in accordance with 
the European Communities Council Directive. CSF was collected from the cisterna 
magna, assessed for blood contamination analysis as previously described[199] and 
stored at -80 °C. Blood was collected from the inferior vena cava in syringes containing 
EDTA as anticoagulant, followed by centrifugation at 1000 × g for 20 min at room 
temperature (RT). Plasma samples were then collected and stored at -80 °C. From each 
removed and dissected brain; hippocampus (divided in two halves) and cortex samples 
were collected and frozen immediately at -80 °C for biochemical analyses. As already 
described, tissue samples from mice that entered the IDIF study were already collected, 
corresponding to hemi-brains of each animal, thus the separation of the hippocampus was 
not possible at this stage. In the present study, only the hippocampus or all brain (for 3 
and 7 months-old mice, respectively), were used and analyzed in the subsequent assays. 
 
Sample preparation 
Hippocampus samples were homogeneized in 300 μL of kinexus lysis buffer (20 mM 
MOPS pH 7.0; 2 mM EGTA; 5 mM EDTA; 30 mM sodium fluoride; 60 mM β-
glycerophosphate pH 7.2; 20 mM sodium pyrophosphate; 1 mM sodium orthovanadate; 
1% Triton X-100) and 1mM phenylmethylsulphonyl fluoride (PMSF) and protease 
inhibitors (PIs – stock at 100x). In relation to the other group of mice and since the all 
brain samples had already been collected and frozen in 500 μL of a different lysis buffer 
(TBS 50mM pH 7.4; 0.2% Triton X-100; 4mM EDTA; and PIs), it was necessary to 
prepare a kinexus lysis buffer 2x. By adding 500 μL of kinexus 2x (plus 2 mM PMSF and 
2x PIs) we were able to equalize the conditions of the all brain and hippocampus samples. 
The homogenized samples were then centrifuged for 20 minutes at 14 rpm (4 °C), 
supernatants were collected and total protein concentration was determined using the 
Bradford method. After quantification, hippocampus and all brain samples were diluted to 
2 mg/mL and 3 mg/mL, respectively. All samples were then boiled for 5 minutes with 1x 
SDS buffer (125 mM Tris pH 6.8; 4% SDS; 20% glycerol; 10% β-mercaptoethanol; and 
0.08% bromophenol blue) and stored at -20 ºC for future analysis. 
FCUP/ICBAS  45 
  Material and methods 
Western Blot 
Proteins were separated by 10% SDS-PAGE (200V; 25mA; ~1.30h), and transferred 
(100V; 400mA; 2h) to a nitrocellulose membrane (WhatmanTM GE Healthcare Life 
Sciences – Protran BA 83), using a wet system (Bio-Rad Criterion Blotter). Membranes 
were blocked using blocking buffer, 10% bovine serum albumin/nonfat dry milk (BSA/DM 
depending on the antibody) in phosphate-buffered saline containing 0.05% Tween-20 
(PBS-T), for 1 hour at room temperature with gentle shaking. Alternatively, samples were 
separated using commercial gradient gels – Criterion XT Precast Gel, 4-12% 
polyacrylamide Bis-Tris, 18 well (#345-0124 Bio-Rad) using the recommended XT MES 
Running Buffer (#161-0789 Bio-Rad). After the electrophoresis (200V; 250 (maximum) 
mA; ~35min), proteins were transferred (100V; 400mA; 2h) to a nitrocellulose membrane 
(WhatmanTM GE Healthcare Life Sciences – Protran BA 83), using a wet system (Bio-Rad 
Criterion Blotter). The membrane was dried, boiled 10 minutes with PBS, washed also 
with PBS, and followed the common protocol above specified. 
Antibody incubation 
After blocking, membranes were then incubated with primary antibodies against the 
proteins under study. After optimization of different variables such as dilution of primary 
and secondary antibodies, incubation conditions (solution and incubation time), type of gel 
and reference protein, the best conditions were established for each protein of interest 
and are summarized in Table 1. After the incubation with primary antibodies, membranes 
were washed 3 times for 10 minutes, followed by the suitable secondary antibody (anti-
rabbit-HRP conjugated – AP311; The Binding Site – or anti-mouse-HRP conjugated – 
#31432; Pierce Antibodies ) both diluted 1:5000, in 3% (1% when incubated with anti-α-
tubulin) DM/PBS-T, for 45min at RT with gentle shaking. The blots were developed using 
Immun-Star™ WesternC™ Chemiluminescence kit (Bio-Rad) and proteins were detected 
and visualized using a chemiluminescence detection system (ChemiDoc, BioRad). When 
necessary, membranes were stripped using a commercial stripping buffer (Re-Blot Plus 
Solution (10x) – Millipore) during 20min at RT with gentle shaking, for re-utilization of the 
membrane, according to the manufacturer’s instructions. Protein levels were normalized 
using the ratio between the protein of interest and α-tubulin. 
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Protein 
Primary 
Antibody 
Dilution 
Incubation 
conditions 
Protein loaded (μg) 
/ type of gel 
Sortilin 
rabbit - ab16640;  
Abcam 
1:1 000 / 
2 000* 
5% BSA/PBS-T, 
O/N at 4°C 
30 / 10% SDS-
PAGE 
Synaptophysin 
mouse - 
ab18008;  
Abcam 
1:2 000 / 
5 000* 
5% DM/PBS-T, 
O/N at 4°C 
30 / 10% SDS-
PAGE 
α-APP C-
terminal 
rabbit - A8717; 
Sigma 
1:10 000 
5% BSA/PBS-T, 
1h at RT 
50 / 4-12% PolyA 
Bis-Tris 
β-Amyloid N-
terminal 
mouse - A5213; 
Sigma 
1:10 000 
5% BSA/PBS-T, 
1h at RT 
50 / 4-12% PolyA 
Bis-Tris 
α-Tubulin 
mouse - T8203; 
Sigma 
1:10 000 
5% DM/PBS-T, 
1h at RT 
30 / 50** 
Table 1. List of antibodies used in Western Blot analyses. (*) Dilution of antibody suggested by the manufacturer / 
optimized dilution used in subsequent analysis. (**) The quantity of loaded protein varies according to the protein of interest 
being analyzed and type of gel necessary for this analysis. 
 
Statistical Analysis 
Quantitative data are presented as Mean ± SEM. Statistical analysis was carried out 
using Graphpad Prism 5 software. First of all, data was assessed whether it followed a 
Gaussian distribution by the Kolmogorov-Smirnov test. When found to follow Gaussian 
distribution, differences among groups were analyzed by one-way ANOVA (followed by 
Bonferroni's Multiple Comparison Test) and comparisons between two groups were made 
by Student’s t test. In the cases of non-Gaussian distribution, differences among groups 
were analyzed by non-parametric Kruskal-Wallis test (followed by Dunns test). p values 
lower than 0.05 were considered significant. 
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Results 
Previous work showed that the AD/TTR mouse colony established in our laboratory is 
a suitable model to study AD, in particular the neuroprotective role of TTR and gender 
differences in AD[175], as elevated brain levels of Aβ42 were observed in particular in 
AD/TTR+/- female mice as compared to their AD/TTR+/+ counterparts. AD/TTR-/- mice 
which are also generated in this colony, were also used in the present; however, and as 
previously described, the negative effects of the genetic reduction of TTR were not always 
observed in AD/TTR-/- animals compared to AD/TTR-/+ and AD/TTR+/+ littermates. This 
may be due to compensatory mechanisms generated by these animals as hypothesized 
by Oliveira and co-workers in the first characterization of this model[175]. Thus we choose 
not to present these data. 
 In the first characterization of this model, mice of 3, 6 and 10 months were evaluated 
for Aβ brain levels, as assessed by Aβ40 and Aβ42 peptides levels in brain homogenates, 
in two fractions: detergent-soluble fraction, corresponding to Aβ initial aggregates and 
oligomers; formic acid-soluble fraction, corresponding to higher ordered aggregates. In 
addition, Aβ burden was also evaluated by immunohistochesmistry, revealing that plaque 
formation started at the age of 6 months. Younger mice were only investigated for TTR 
levels in plasma, and compared to non-transgenic animals, revealing that TTR is early 
decreased, although its levels were raised in 10 months old mice, probably due to 
compensatory mechanism. However, the effects of TTR genetic reduction in pathways 
known to be altered in AD were not addressed in young mice, before the development of 
disease. As stated in the beginning of this thesis, Alois Alzheimer hypothesized that AD 
occurs due to neuronal failure, and thus this work focused on the search of AD biomarkers 
(proposed to be involved in neuronal failure) early affected by TTR, before Aβ deposition, 
using the AD mouse model described. Then, the results were compared to older mice, at 
an age known to already present Aβ deposition in the brain. In addition, mice that 
underwent treatment with IDIF, known to stabilize TTR and improve AD features, were 
also investigated to further validate the results, and to address the possibility of using 
these biomarkers for disease progression evaluation and follow-up of therapies. In 
particular we measured the levels of sortilin (Sort1), synaptophysin (Syp), APP expression 
and APP processing. 
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Sortilin: expression and quantification 
To investigate if TTR affects Sort1 levels in the brain, we used western blot analysis of 
brain extracts. Based on literature, Sort1 protein is expressed all over the brain, without a 
preferred expression area.  Nevertheless, it is necessary to take in account that AD is 
characterized mainly by alterations in the hippocampus, thus, the results obtained from all 
brain (7 months old mice, with and without IDIF treatment) must be compared to the ones 
in hippocampus, with caution. 
Analysis of sortilin expression in 3 month-old mice 
We started by analyzing Sort1 proteins levels in hippocampus of 3 months-old mice 
(Figure  12), and we found AD/TTR+/- mice presented significantly lower levels of sortilin 
when compared to AD/TTR+/+ animals (p<0.01), (Figure  12B, left panel). Further analysis 
of the results by gender showed no significant differences between AD/TTR+/+ and 
AD/TTR+/-, either in male and female (Figure 12B, right panel). It is important to refer that 
these results are probably influenced by the small number of animals (n=3), in each 
group. Nevertheless, we can observe that the levels of Sort1 tend to decrease from 
AD/TTR+/+ to AD/TTR+/- (male and female) and also vary in gender (lower levels of Sort1 
in female).  
Altogether, these results suggest that TTR influences Sort1 expression at this age, 
before Aβ deposition. 
Analysis of sortilin in 7 month-old mice 
To further understand if the effect of TTR genetic reduction on Sort1 levels was 
sustained overtime, we analyzed 7 months-old mice. Additionally, the study was also 
performed in brain tissue of 7 months-old animals that received IDIF, orally, for 2 months. 
As reported, IDIF administration resulted in lower Aβ deposition in the brain as well as 
cognitive improvements. Thus, we also intended at investigating the possibility of using 
Sort1 as a biomarker, both for disease progression and for follow-up of therapies. As 
already referred, brain tissue (all brain) was already available in the laboratory and 
originated only from females[184]. 
Our results (Figure 13) indicated that Sort1 was significantly decreased in AD/TTR+/- 
compared to AD/TTR+/+ female mice (p<0.001). This indicates that, either the difference 
was accentuated with ageing, or that we could not detect statistic differences in 3 months 
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old mice due to the lower number of samples, as already suggested. Control and treated 
mice, from the same genotype, showed no significant differences in Sort1 levels (Figure 
13B), indicating that TTR stabilization by IDIF did not affect sortilin. 
 
A 
 
B 
 
Figure 12. TTR influences sortilin expression in 3 months-old mice. Western blot analysis of sortilin expression (A) and 
respective quantification (B) grouped by genotype (left panel, n=6 in each group) and by gender (right panel, n=3 
male/female in each group). Data represent the means ± SEM. Error bars represent SEM. **p < 0.01 in a Student’s t test. 
Altogether, our results suggest that Sort1 is primarily affected by TTR quantity, and 
that TTR stabilization alone is not sufficient to recover Sort1 levels. In addition, it seems 
that Sort1 levels correlate positively with disease severity. 
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B 
 
Figure 13. TTR influences sortilin expression in 7 months-old mice. Western blot analysis of sortilin expression (A) in 7 
months-old mice, and respective quantification (B) of AD/TTR
+/+
 control (n=7) and treated (n=7), and AD/TTR
+/-
 control (n=8) 
and treated (n=9) groups. Data represent the means ± SEM. Error bars represent SEM. ***p < 0.001 in one-way ANOVA, 
with Bonferroni’s post test. 
 
Synaptophysin: expression and quantification 
Similar to Sort1 quantification, we performed western blot analysis to investigate if 
TTR affects synaptophysin (Syp) levels in the brain (Figure 14A). Based on literature, Syp 
protein is expressed all over the brain, not having a special area of expression. Again, 
comparison between data obtained for the hippocampus and for all brain must be done 
with caution since, as referred, AD affects in first instance the hippocampus. 
Analysis of synaptophysin expression in 3 month-old mice 
Our results indicated that Syp levels were significantly elevated in hippocampus from 
AD/TTR+/- compared to AD/TTR+/+ mice (Figure 14B, left panel; p<0.05). In addition, it also 
seems that Syp’s levels tend to be increased in female mice (Figure 14B, right panel). 
Again, the low number of animals in each group might explain the lack of statistical 
significance. Thus, Syp expression is suggested to be affected by the variation of TTR 
expression. 
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Figure 14. TTR influences synaptophysin expression in 3 months-old mice. Western blot analysis of synaptophysin 
(Synapto) expression (A) and respective quantification (B) grouped by genotype (left panel, n=6 in each group) and by 
gender (right panel, n=3 male/female in each group). Data represent the means ± SEM. Error bars represent SEM. ***p < 
0.001 in a Student’s t test. 
 
Analysis of synaptophysin expression in 7 month-old mice 
Contrary to the differences observed between TTR/AD+/- and TTR/AD+/+ in 7 month-old 
mice for the expression of Sort1, Western Blot analysis (Figure 15A) of Syp in these 
animals did not show any significant differences between AD/TTR+/- and AD/TTR+/+ female 
mice (Figure 15B), although a trend was observed. IDIF administration produced no 
significant effects on Syp expression. 
Altogether, these observations indicate that the initial alterations in this protein were 
not maintained with ageing and its levels compensated. Curiously, this behavior might 
prompt Syp as an interesting biomarker allowing identification of early phases of disease 
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development, and distinguishing from advanced stages. Nevertheless, Syp will not serve 
as a biomarker for follow-up of therapies, at least the ones associated to TTR stabilization.  
 
A 
 
B 
 
Figure 15. Synaptophysin expression in 7 months-old mice. Western blot analysis of synaptophysin (Synapto) 
expression (A) in 7 months-old mice, and respective quantification (B) of AD/TTR
+/+
 control (n=6) and treated (n=7), and 
AD/TTR
+/-
 control (n=8) and treated (n=9) groups. Data represent the means ± SEM. Error bars represent SEM. 
 
APP expression and processing: C-terminal 
Since Aβ, the key peptide in AD and thought to be the causative agent in this disorder, 
is generated upon APP processing, which in turn can be affected by sortilin, we then 
inquire whether APP expression and APP processing was altered by genetic decrease of 
TTR, using for the purpose, an anti-APP antibody, which is specific to the C-terminal of 
human APP695 (amino acids 676-695). This sequence is identical in APP751 and APP770 
isoforms, corresponding to the last 20 aa, and thus enabling full lenght APP quantification. 
In addition to APP, it recognizes the C-Terminal Fragments (CTFs) – CTF-β (99 aa; MW 
~13 kDa ); CTF-α (83 aa; MW ~10 kDa ); and CTFγ (or AICD; 57 aa; MW ~6.5 kDa). This 
will allow us to deduce about the effect of TTR in APP processing, through the 
quantification of each CTFs. 
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Analysis of APP expression and processing in 3 month-old mice 
While analyzing the expression of APP in this cohort, we were not able to see 
significant differences between groups with different genotypes and genders (Figure 16A 
and B). Graphic analysis showed that the expression of APP is similar in the different 
groups, thus suggesting no influence of TTR in APP expression, as ascertained by 
Western Blot. In order to ascertain whether APP processing was influenced by TTR we 
started by analyzing the CTFs. Using the same blot membrane that was used for total 
APP expression (Figure 16A), but increasing exposure time,  we were able to observe 
with higher resolution two bands, of which we identified the first as being the CTF-β-
corresponding band. In addition, we suggest that the second band may be an N-terminally 
truncated APP CTF-β (CTF-β’, composed by 89 aa), a product of β-cleavage of APP at 
residue 10. The results are depicted in Figure 16C and are presented as a ratio between 
levels of CTFs and full lenght APP. No differences were observed between AD/TTR+/+ and 
AD/TTR+/- mice, neither for CTF-β (Figure16C left panel) nor for CTF-β’ (quantification 
data not shown) suggesting TTR does not influence APP processing, at this age. 
Analysis by gender also did not show any significant differences, although a trend for 
increased CTF-β can be considered in female when compared to male, and in AD/TTR+/- 
when compared to AD/TTR+/+ also in the female groups (Figure 16C right panel). If these 
results are confirmed, this indicates that in female and in particular in female AD/TTR+/-, 
APP preferentially undergoes the amyloidogenic processing, explaining the higher degree 
of AD-like disease described in this model. 
Analysis of APP expression and processing in 7 month-old mice  
Next, the same full length APP and CTFs analysis assessed by Western Blot was 
performed for the 7 months-old mice brain samples (Figure 17A), to further characterize 
the influence of TTR in APP expression and processing, as disease develops. In terms of 
APP protein levels, we found no significant differences between AD/TTR+/+ and AD/TTR+/- 
groups (Figure 17B, upper panel), thus, suggesting that TTR had no effect on APP 
expression. Following the same line of thought – considering that the two bands 
correspond to CTF-β and CTF-β’ (Figure 17A) – we were able to observe increased levels 
of both forms of CTFs in AD/TTR+/- female mice when compared to their littermates 
AD/TTR+/+ (Figure 17B, lower panels). This suggests that TTR influences APP processing, 
and that TTR reduction stimulated the formation of both CTF-β, thus promoting the 
amyloidogenic pathway. 
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Figure 16. TTR effects on the amyloid precursor protein (APP) expression and processing in 3 months-old mice. 
Western blot analysis of APP and carboxi-terminal fragments (CTFs) expression (A) and respective quantification (B and C, 
respectively) grouped by genotype (left panel, n=6 in each group) and by gender (right panel, n=3 male/female in each 
group). Data represent the means ± SEM. Error bars represent SEM. 
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Analysis of IDIF treated mice samples revealed no differences when compared to the 
non-treated mice of the same age (data not shown), again suggesting that the quantity of 
TTR is determinant for its effects in APP processing, and stabilization of the protein per se 
does not compensate its genetic reduction. 
 
APP expression and processing: N-terminal 
APP processing also results in N-terminal fragments sAPPα or sAPPβ, depending if 
cleaved by α- or β-secretases, respectively. While sAPPα is considered neuroprotector 
and to induce the expression of survival genes, sAPPβ has been shown to act as a death 
receptor ligand, mediating neuronal death. 
To assess the levels of sAPPα as well as the levels of Aβ peptide, we performed 
Western Blot analysis using a specific antibody that recognizes amino acid residues 1-12 
of the Aβ peptide sequence. This antibody allows the recognition of sAPPα and Aβ 
peptide, as well as full lenght APP. 
Analysis of APP expression and processing in 3 month-old mice  
Despite using a specific antibody to detect the Aβ peptide, its corresponding band was 
not observed (data not shown), probably due to its normally low levels. However, we were 
able to detect and quantify the total APP and sAPPα bands (Figure 18A). While total APP 
levels were normalized using α-tubulin protein, sAPPα levels was again normalized using 
full lenght APP expression. 
Differences between AD/TTR+/+ and AD/TTR+/- were not significant, neither for full 
lenght APP (Figure 18B, left panel) nor for sAPPα (Figure 18B, right panel), suggesting 
that TTR does not influence neither APP expression (as seen in the previous section), nor 
APP processing (leading to the formation sAPPα), at this age. Analysis by gender also did 
not demonstrate significant differences between none of the groups (data not shown).  
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Figure 17. TTR influences APP processing, in 7 months-old mice. Western Blot analysis of 7 months-old AD/TTR
+/+
 
control (n=7) and AD/TTR
+/-
 control (n=8) mice groups, in terms of full length APP and CTFs (between 15 and 10 kDa) 
expression. Data represent the means ± SEM. Error bars represent SEM. *p < 0.05 in Student’s t test. CTFs values are 
show as a ratio between the quantification of the CTF-corresponding band and the quantification of APP-corresponding 
band. 
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Figure 18. TTR effects on APP processing and expression in 3 months-old mice. Western Blot analysis of full length 
APP and sAPPα expression (A) and respective quantification (B, left panel and right panel, respectively) grouped by 
genotype (n=6 in each group). CTFs bands were not possible to identify. Data represent the means ± SEM. Error bars 
represent SEM. 
Analysis of APP expression and processing in 7 month-old mice 
The same full length APP analysis was performed in 7 months-old AD/TTR+/+ and 
AD/TTR+/- mice samples (control and treated) (Figure 19A), and no significant differences 
were observed (Figure 19B). Curiously, and differently from the 3 month old mice, we 
could not detect the band corresponding to sAPPα (see Figure 19A). This may indicate 
that cleavage by α-secretase is decreased (in favor of β-secretase), thus explaining the 
increased Aβ brain levels found in these older mice and corresponding signs of AD-like 
disease. These findings are, apparently, unrelated to the TTR genetic reduction and to its 
conformational state (tetrameric stability), and appear to depend only on disease 
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progression, since we observed no differences neither between TTR/AD+/+ and TTR/AD+/- 
nor between treated and non-treated mice. It is also possible that the age/disease 
progression effect is stronger that the effect of TTR reduction, and thus subtle differences 
between genotypes were not detected. In this case, a new analysis using a different, more 
sensitive, antibody or loading higher amounts of total protein in the gel, may help 
answering to this question. 
 A 
 
B 
 
Figure 19. TTR effects on APP processing and expression in 7 months-old mice. Western Blot analysis in 7 months-
old mice of full length APP expression (A) and respective quantification (B). The analysis included AD/TTR
+/+
 control (n=7) 
and treated (n=7), and AD/TTR
+/-
 control (n=8) and treated (n=9) groups. In addition to the CTFs bands not possible to be 
identified, sAPPα bands were not observed. Data represent the means ± SEM. Error bars represent SEM. 
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Discussion 
Alzheimer’s disease is the most prevalent form of dementia, worldwide. However, due 
to its complexity, most of the molecular mechanisms responsible for the pathological 
features remain unsolved. In addition to the little existing knowledge of molecular 
mechanisms, there are not any efficient drugs to treat AD, merely its symptoms. 
Therefore, a logical option is to discover this condition in its early stages, when the 
“treatment” can be more effective, and so it urges to find specific biomarkers that can 
differentiate an early stage AD patient, from a control. A variety of factors can be involved 
in the initiation and progression of AD and, among them, TTR has been shown to be an 
important modulator of AD pathogenesis, using mouse models. Thus, in this project, we 
intended to draw some conclusions about the influence of TTR on some proposed 
biomarkers, using a transgenic AD mouse model in different TTR genetic backgrounds 
(AD/TTR)[175], previously described by Oliveira and group. In this model, mice in a TTR 
hemizygous background are presented with a more severe form of AD-like disease, in 
particular female mice [175]. 
We started to investigate whether TTR had any influence in sortilin (Sort1) 
expression in hippocampus/all brain samples of transgenic AD mice, and if this effect was 
modified with aging. Our analysis showed a significant decrease in Sort1 expression in 3 
and 7 months-old AD/TTR+/- animals, when compared to their AD/TTR+/+ littermates. This 
suggests that TTR, indeed, influences Sort1 expression, in a way that its genetic decrease 
correlates with decreased Sort1 levels. Our observations agree with several recent works, 
namely with Finan et al. study from 2011, in which the authors showed decreased levels 
of Sort1 in AD post-mortem brain samples, compared to control [189]. In our work we did 
not use non-transgenic mice and thus we cannot assert differences in Sort1 expression 
levels between controls and AD-like samples. Nevertheless, we were able to compare its 
expression in AD/TTR+/+ and AD/TTR+/- groups, establishing an inverse relation with 
disease progression, and thus, we hypothesized that Sort1 levels in control animals 
should be increased (agreeing with the literature). This is further supported by the 
observation that, in female, differences in Sort1 levels between AD/TTR+/+ and AD/TTR+/- 
are more pronounced in 7 months-old than in 3 months-old mice samples. Gustafsen et 
al. also stated a probable decrease of Sort1 expression in AD pathology, proposing Sort1 
as an APP sorting receptor, which promotes the cleavage by α-secretase, inhibiting Aβ 
formation [190]. In addition, they referred that Sort1 also interferes with the production of 
soluble forms of APP and its cellular uptake, guiding it to lysosomal degradation. Thus, a 
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decrease in Sort1 levels would diminish would interfere with the above mentioned 
pathways, consequently promoting Aβ production and the progression of the disease. In 
our work, we showed that APP expression was not altered at any ages, contrary to its 
processing. Although in 3 months-old mice, no significant differences were obtained for 
total CTFβ levels (in which we consider both CTFβ and CTFβ’), when considering TTR 
background, a trend for increased CTFβs was observed in female, compared to males, in 
particular in AD/TTR+/-. Importantly, significant differences were measured in 7 months-old 
animals as AD/TTR+/- presented higher levels of CTFβ and CTFβ’ than AD/TTR+/+ 
females, thus suggesting that besides age/disease progression, TTR also affects APP 
processing. In addition, in younger mice we were able to observe the sAPPα band, 
whereas in 7 months-old mice this band was absent. This meets the previous suggestion 
that a decrease of Sort1 would diminish α-secretase activity, and thus indirectly promoting 
the amyloidogenic pathway, showed by increased levels of CTFβ in AD/TTR+/- older mice. 
The presence of a visible sAPPα band in 3 months-old mice and its absence in 7 months-
old mice, shows a consistency in results. Younger mice, present, in both TTR genotypes, 
the sAPPα band but do not show any difference between CTFβ levels; the opposite is 
observed for older mice.  This shows that aging is an important factor that may overlap the 
influence of TTR reduction in APP processing, since both ages present decreased levels 
of Sort1 but only the 7 months-old mice suggest an unbalance in the amyloidogenic and 
non-amyloidogenic pathway. Another group also considered that Sort1 expression is 
diminished in AD, despite suggesting a different molecular mechanism for its relation with 
this disorder [186]. Carlo et al. suggest that Sort1 acts as a neuronal receptor for ApoE, 
thus being involved in ApoE/Aβ complex clearance from the brain; the lack of Sort1 
receptor expression leads to increased ApoE and Aβ accumulation in the brain, resulting 
in disease escalation. Plus, they noticed a two-fold lower Kd for binding to Sort1, by ApoE 
ε3 (44 nM) versus ApoE ε4 (114nM)[186], which might be related to the different isoforms’ 
risk in AD. In our work we did not assess ApoE levels, and thus we cannot infer on the 
mechanism underlying TTR/Sort1 relation. In the future, it would be interesting to 
investigate ApoE levels as well as a possible TTR/Sort1 interaction. In relation to the 
effects caused by the IDIF treatment, we show that no significant differences between 
control and treated mice, of the same genetic background, suggesting that despite TTR 
genetic reduction influenced Sort1 levels, its stabilization with IDIF was not enough to 
induce an alteration in Sort1 levels of treated mice. Thus we propose that the quantity of 
TTR, and not its stabilization state, is a major factor in the influence of Sort1. This also 
indicates that the beneficial effects of TTR stabilization by IDIF on AD features in this 
mouse model does not involve sort1, implying that TTR plays a role in AD pathogenesis 
via different pathways. 
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Data on the behavior of synaptophysin (Syp) expression is quite contradictory in the 
literature. While some suggest a decrease of Syp levels in AD, comparing to control[195, 
196], others argue the opposite, despite acknowledging a negative correlation between Aβ 
accumulation and a decrease in Syp expression[194, 195]. Another study has shown that 
Syp is a probable γ-secretase-associated protein since its inhibition (using siRNA) 
resulted in a decrease of Aβ40 and Aβ42 levels[200], demonstrating a positive correlation 
between Syp’s expression and Aβ levels. It goes without saying that this inconsistency is 
also the reflex of the lack of knowledge of Syp-related molecular mechanism in AD. Our 
results showed a significant increase in Syp expression in 3 months-old AD/TTR+/- mice, 
compared to AD/TTR+/+ littermates, suggesting that TTR genetic reduction influences Syp 
expression; again, female mice showed a trend for higher Syp levels. As for the 7 months-
old mice, no significant differences in Syp expression were observed between AD/TTR+/+ 
and AD/TTR+/- female mice, although a tendency for increased levels of Syp was 
observed in the later. Because we did not perform a comparative study for the same TTR 
background at the two different ages evaluated, we were not able to distinguish if Syp 
levels increased in AD/TTR+/+ or diminished in AD/TTR+/-, comparing the 3 month to the 7 
months-old animals. The inability to conclude on Syp behavior in our model is further 
complicated since we did not analyzed non transgenic animals, and therefore we did not 
ascertained Syp normal levels. In addition, the relative comparison between the two 
different ages evaluated is made between hippocampus and all brain, for the 3 and 7 
months-old mice, respectively, which might have influenced the results. This limitation 
applies to all analysis performed and should be properly addressed in future experiments. 
Again, with regard to the effects of IDIF administration on the molecules under study, our 
data clearly indicated that TTR stabilization was not sufficient to restore their levels, and 
that TTR quantity is, at least in a first instance, a limiting factor, in opposition to effects on 
Aβ levels and deposition which were decreased in AD/TTR+/- IDIF treated mice when 
compared to non-treated[184]. In our opinion, AD-increased Syp levels are easily 
accepted, if one only looks at its molecular mechanism: if Syp expression ought to be 
increased, neurotransmission would be compromised, which would lead to the 
characteristic synaptic failure in AD. However, with the pathological evolution of AD 
(oxidative stress, SPs and NFTs formation, etc), the death of neurons and, subsequently, 
the destruction of synapses will lead to a natural decrease in Syp levels. In relation to the 
possible role of Syp as a γ-secretase-associated protein, we only observe a coherent 
behavior in 3 months-old mice[200]. Nonetheless, it is important to take into account that 
their study was performed in vitro, and that compensatory mechanism are triggered very 
often in vivo, especially in such complex diseases. Altogether, these observations prompt 
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Syp as a prospective and interesting biomarker that would allow the highly desirable 
detection of AD at its earliest stages. 
In summary, our results showed differences in Sort1, Syp and APP processing 
dependent on the TTR background, further highlighting the importance of TTR in AD. Our 
observations also strengthened the in vivo evidence that this model is suitable for the 
study of the neuroprotective role of TTR and gender differences in AD as, in general, 
females showed more accentuated differences, thus recapitulating the trend observed for 
humans[201]. 
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Conclusions 
Two important notions to retain through the analysis of this work are: it is based on a 
single technique – Western Blot – which is a poor technique for the quantification of small 
changes, and on the analysis of hippocampus versus all brain, from mice of 3 and 7 
months of age, respectively.  The study performed in all brain can potentially result in the 
loss of specific alterations in the hippocampus, known to be particularly and early affected 
in AD. Future research should address this limitation and a higher number of mice 
hippocampus samples of different ages should be evaluated. In addition, future work 
should also include non-transgenic mice allowing the determination of Sort1 and Syp 
normal levels in the strain of mice used, in order to correctly conclude on the increase or 
decrease of these molecules in AD/TTR+/+ versus AD/TTR+/- animals. 
With regard to the influence of TTR in Sort1 and Syp expression and in APP 
processing, interaction studies between TTR and Sort1/Syp proteins are necessary to 
access whether their alteration is a direct or indirect effect caused by TTR genetic 
reduction. Cellular studies, in a more controlled environment, should also be engaged and 
would also enable us to confirm the effects of TTR in these molecules. 
Sort1 showed to be influenced by TTR and presented some features that could allow 
Sort1 to be considered a biomarker for early detection of AD and for follow-up of AD 
therapies. As for Syp, it also showed to be influenced by TTR (in younger mice) and, 
interestingly, it showed to be highly affected by aging, independent of TTR genotype. This 
feature could allow Syp to be used as an early AD detection biomarker, prior to Aβ 
accumulation. The alterations in each molecule must be specific of AD and being AD such 
a complex disorder, association and combination of biomarkers will increase the chances 
of success. 
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